GENAISSANCE: Der Inbegriff der Zukunft zum Dumpingpreis/Teil2 - 500 Beiträge pro Seite

[Neoe]

Sorry an alle , die diesen Thread bisher verfolgt und auch gepostet haben. Ich lege diesen Thread aus bestimmten Gründen nochmal neu auf.
Die bisherigen Postings findet ihr hier nochmal.
Übrigens:Bid 2,04$
Ask 2,09$

[Neoe]

Die Grundlageninfo:

#1 von Neoe 07.05.02 23:07:43 Beitrag Nr.: 6.357.817 6357817
Dieses Posting: versenden | melden | drucken
Genaissance(Nasdaq-NM:GNSC) ist ein Pharmacogenomics-Unternehmen ;heißt, sie versuchen Medikamente auf die persönliche Verträglichkeit abzustimmen , indem sie die genetische Ursache von Nebenwirkungen aufdecken und so gezielt sagen können , wer welches Medikament verträgt.

Die unglaublichen Facts:

Cash:50 Mio $
Total assets:79 Mio $
Marktkap.:42 Mio $ !!!!!!!!!!!
Shares out: 23 Mio.
Share price:1,65 $

Die großen der Pharmabranche sind bereits Feuer und Flamme. Die Absatzzahlen für bestehende Medikamente könnten sich anscheinend verzehnfachen und das Risiko, daß ein Medikament wegen unerwünschter Nebenwirkungen in Einzelfällen nicht zugelassen wird ,verringert sich erheblich , da die Nebenwirkungen mit bestimmten genetischen Vorraussetzungen in Verbindung gebracht werden können. Anstatt gleich das gesamte Medikament zu kippen , werden zukünftig die nicht geeigneten Patienten herausgefiltert.

Kundenliste gefällig (steht im Q1-Report auch nochmal):

Pharmas:
ASTRA ZENECA
PFIZER
JOHNSON&JOHNSON

Biotech:
BIOGEN

Der folgende Quartalsbericht sollte alle Fragen beantworten.
Leßt ihn euch aufmerksam durch , einzig negativ ist die Cashburnrate. Aber die Kohle wird bis zum break even reichen.





Genaissance Pharmaceuticals Reports First Quarter Results

Quarter Highlighted by Commercial Progress, Significant Reduction
In Operating Expenses, and Strong Data From STRENGTH I Trial

NEW HAVEN, Conn., April 26 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today reported its financial results for the first quarter ended March 31, 2002.

For the three months ended March 31, 2002, revenues were $1.9 million, compared to $1.0 million for the first quarter last year. Operating expenses for the quarter were $10.7 million, of which $8.2 million were attributable to research and development. This compares to operating expenses of $13.0 million and research and development expenses of $9.9 million for the first quarter of 2001. The Company reported a net loss for the quarter of $9.1 million or $0.40 per share, compared to a net loss of $11.2 million or $0.49 per share for the same period last year.

Operating expenses decreased significantly from $15.0 million in the fourth quarter of 2001 to $10.7 million in the first quarter of 2002, a decrease of nearly 30 percent. This decrease reflects the completion of patient recruitment and associated costs from the STRENGTH trials as well as a continuance of reduced spending levels now that the Company`s infrastructure is fully in place. The Company believes that its business model is scalable and its current cost structure will support its planned revenue increases for 2002.

As of March 31, 2002, the Company had cash, cash equivalents and marketable securities totaling $50.1 million.

"Our first quarter results reflect our heightened efforts toward commercializing our technology, while prudently managing our financial resources," said Gualberto Ruano, M.D., Ph.D., Chief Executive Officer of Genaissance. "We gained momentum in the commercial arena with a breakthrough agreement with Biogen and, with our ongoing analysis of the STRENGTH data, we are discovering HAP(TM) Markers which we believe will have important commercial value to the growing cholesterol management market."

Highlights of the quarter include:

-- Genaissance signed an agreement with Biogen, one of the world`s
premiere biotechnology companies, in which Genaissance`s HAP(TM)
Technology will be applied to drugs currently in Biogen`s product
pipeline and to drug targets under investigation. This is the first
time Genaissance`s technology will be used on a product already in
clinical development and is the first time that the technology will be
used to pair a pharmaco-genomics test with a drug for use in marketing.
The Company believes this collaboration represents a new marketing
paradigm and sets the tone for further drug specific collaborations.

-- Ongoing analyses of the STRENGTH I Study further demonstrated the
ability of HAP(TM) Technology to identify genetic markers that are
associated with the effects of statin therapy. Of the HAP(TM) Markers
examined so far, 25 were linked to drug-specific clinical responses for
simvastatin (Zocor(R)(1)), atorvastatin (Lipitor(R)(2)) or pravastatin
(Pravachol(R)(3)). The Company believes these important findings
strengthen the commercial value of its HAP(TM) Markers for the
development of pharmaceutical and diagnostic products.

-- Genaissance launched the CARING (Clozapine and Agranulocytosis
Relationships Investigated by Genetics (HAP(TM) Markers)) Study during
the quarter, which is designed to discover genomic markers for
identifying patients at risk of clozapine-induced agranulocytosis, a
potentially life-threatening depletion of white blood cells. Clozapine
is a highly effective treatment for schizophrenia but its use is
limited, in part, because of the risk of agranulocytosis and the
requirement for those on the drug to undergo repeated blood monitoring.
By discovering HAP(TM) Markers that predict which individuals will be
at risk of developing agranulocytosis, Genaissance hopes to reduce or
eliminate the need for blood monitoring so that its HAP(TM)-Clozapine
will be of benefit to more patients and, therefore, more widely
prescribed.

-- Realizing the importance and breadth of the Japanese market,
Genaissance signed an agreement with INTEC W&G Corporation, a leading
Japanese bioinformatics and advanced research business, to market
Genaissance`s proprietary pharmacogenomics applications and products to
pharmaceutical, biotechnology and diagnostic companies located in
Japan. Japan is the second largest pharmaceutical market in the world
and is home to nearly 600 biopharmaceutical companies.


With respect to the full year 2002, the Company reiterates its prior revenue guidance and issues the following reduced operating expense and cash usage projections:

-- Revenues for the year to be between $10 and $15 million
-- R&D spending for the year to be between $30 and $32 million
-- SG&A spending for the year to be between $10 and $11 million
-- Projected net loss for the year to be between $30 and $33 million
-- Cash usage for the year to be between $30 and $33 million


"We are pleased by the variety of deals that we have completed utilizing Genaissance`s pharmacogenomics content and continue to see an increase in our business development activities," said Kevin Rakin, President and Chief Financial Officer of Genaissance. "With an established infrastructure and a growing acceptance of the value of pharmacogenomics, Genaissance is able to aggressively pursue high value business opportunities. Therefore, we anticipate our burn rate decreasing to a target of $20 million for the remaining three quarters of the year."


Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company also has identified candidates for development in its own pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut. Please visit http://www.genaissance.com for additional information.

[Neoe]

#2 von ZittrigeHand 08.05.02 11:52:01 Beitrag Nr.: 6.361.158 6361158
Dieses Posting: versenden | melden | drucken
@ neoe
hast post

#3 von Neoe 10.05.02 22:00:37 Beitrag Nr.: 6.380.935 6380935
Dieses Posting: versenden | melden | drucken
Manipulation hoch 100. Was bei diesem Stock abgeht ist unglaublich. Irgendwas kommt da und ich denke es wird was gutes sein. Man schaue sich mal die time&sales von heute an, nach diesem Schema läuft das schon Tage. Mit 100er Trades wird die Aktie abgeschossen und irgendwann kommen dann riesege Blocktrades. Selber schuld wer nicht merkt was im hier entgeht.
Morgen ist übrigens eine Konferenz.

Senior Executives from Genaissance Pharmaceuticals, Inc., GenVec and Other Companies Will Present to Investors at Biotech/Genomics Stocks Forum
The Forum, to be Held May 11, Will Provide Investors the Opportunity to Hear Analyst-Style Presentations and Question Company Executives Directly by Attending Onsite or Online
RICHMOND, Va., April 30, 2002 (PRIMEZONE) -- A Biotech/Genomics Stocks Forum featuring five companies and an industry expert will be held on May 11. The event is open to the public and will take place at the Sheraton Suites in Alexandria, Virginia and online at www.informedinvestors.com. By attending this Forum, investors can hear directly from company executives and get their investment information straight from the source.

The event, produced by Informed Investors, will take place from 8 a.m. to 12 p.m. Information and registration are available at www.informedinvestors.com or by calling 888-301-6618.

Current and potential investors will hear from Biotech and Genomics sector companies including Genaissance Pharmaceuticals, Inc. (Nasdaq:GNSC) and GenVec (Nasdaq:GNVC). Executives from each company will give 20 minute analyst-style presentations, and a 5-10 minute question and answer session with the investor audience follows each presentation.

The keynote address will be delivered by Dennis E. Ohman, Ph.D. Dr. Ohman is the Chair of the Microbiology & Immunology Department at the Medical College of Virginia Campus of Virginia Commonwealth University. The department is highly research oriented, with a focus on cell and molecular biology, molecular genetics, and immunology. Dr. Ohman also serves as a Research Microbiologist at McGuire Medical Center.

Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company discovers genetic markers (haplotypes) that are predictive of drug efficacy and safety, and markets its haplotype technology and its clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company is also developing its own internal pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top ten pharmaceutical companies: Pfizer, AstraZeneca and Johnson & Johnson. Genaissance is located in Science Park in New Haven, Connecticut. They will be represented by Mr. Kevin Rakin, President and Chief Financial Officer at their 9:45 presentation.

GenVec will be speaking to investors at 11:30. GenVec develops gene-based products that cause the production of therapeutic proteins at the site of disease. GenVec`s current areas of focus are cardiovascular disease, oncology and ophthalmology. GenVec`s product candidates are comprised of genes and gene transfer systems that transport those genes into cells at the site of the disease.

Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink family of companies serving self-reliant investors.

About WILink: Since 1992, WILink (www.wilink.com) has opened information channels between public companies and potential investors. WILink is an investor relations and investment services group that markets a range of services that help publicly traded companies and mutual funds attract and retain well informed investors, while providing investors with access to information to make well informed investment decisions. This year WILink will make more than 7 million investor introductions to over 4,200 corporate clients through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com) Investor Conference (www.investorconference.com) and Informed Investors Forums (www.informedinvestors.com). These services provide investors free access to onsite and webcast investor events and company financial reports through WILink`s relationships with over 220 leading financial media channels in 14 countries including The Wall Street Journal, Financial Times, Barron`s and Yahoo!Finance. For companies and mutual funds, these services enable compliance with regulation fair-disclosure requirements and provide visibility with investors at the precise point investors are making decisions. WILink, Inc., a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange), began operations in Richmond, Va. in 1993.

#4 von belina 10.05.02 23:10:44 Beitrag Nr.: 6.381.385 6381385
Dieses Posting: versenden | melden | drucken
Hi, klingt interessant! Aus welchen Quellen kommen den die
Infos, wo gibts den Chart?

#5 von Neoe 11.05.02 14:33:22 Beitrag Nr.: 6.383.464 6383464
Dieses Posting: versenden | melden | drucken
belina@:
Für die Infos mußt du nicht einmal lange suchen. Auf www.nasdaq.com findest du den letzten Quartalsbericht , der hier ja schon drin ist , weiter kannst du dich dort auch von der lächerlichen Marktkapitalisierung überzeugen.

Die Investorenkonferenz geht gerade los und man kann sie unter www.informedinvestors.com mitverfolgen. Unter uns befinden sich auch noch genug andere , zu unrecht geschundene Brüder.....

#6 von Neoe 11.05.02 15:53:06 Beitrag Nr.: 6.383.706 6383706
Dieses Posting: versenden | melden | drucken
Wichtigste Aussagen:
Geld reicht nach dem Stand von 1.April 02 noch acht weitere Quartale , also bis 1.April 04 , cashburn pro Quartal soll dabei 2003 HÖCHSTENS noch bei 6 Millionen liegen.
Zudem wurde gesagt, daß man mit Johnson&Johnson und Biogen bereits im ersten Quartal 2004 fertige Medikamente im Angebot haben möchte.
Jetzt kann sich jeder selbst ausrechnen , wie es weiter gehen wird. Ich denke das der Verlust auch bis Ende 2003 nicht mehr allzu groß sein wird , da bei erreichen von Meilensteinen gerade aus der Kasse von Biogen , die ja erst seit kurzem mit GNSC zusammenarbeiten , einiges an Geld fließen soll und einige andere "blue chip"-Partner geködert werden sollen.

Und für den, den es interessiert , macht euch mal hier etwas zu schaffen. Scheint als wäre die Tafel zum Anstieg eigentlich schon längst angerichtet.......:
http://iw.thomsonfn.com/iwatch/cgi-bin/iw_ticker?ticker=gnsc…

#7 von Neoe 12.05.02 23:34:50 Beitrag Nr.: 6.389.071 6389071
Dieses Posting: versenden | melden | drucken
Da mein Thread die Höchststrafe erleidet , nämlich Ignoranz , gehe ich davon aus , daß irgendwas mit meinem Investment nicht stimmen kann. Ich kann leider weit und breit nicht erkennen was , vielleicht klärt mich ja einer auf?

#8 von kalabrienfan 13.05.02 12:43:28 Beitrag Nr.: 6.392.007 6392007
Dieses Posting: versenden | melden | drucken
Hallo Neoe,
ich bin seit längerem investiert und habe jetzt nochmal
nachgekauft.
Das ist keine Zockeraktie, sondern eine Langfristanlage.
Damit kann man nicht auf die Schnelle viel Geld verdienen
und deshalb interessiert sich kaum jemand dafür.
Ich finde das gut so, denn wenn die Empfehlungen auch
in Deutschland kommen ( Förtsch und Konsorten )ist es
für mich sowieso an der Zeit, meine Anteile zu verkaufen.
So bin ich eigentlich die letzten 2 Jahre einigermaßen gut
über die Runden gekommen.
Die Cashburnrate ist natürlich wahnsinnig hoch. Ich schätze
mal, die werden früher oder später geschluckt, was unser
Schaden nicht sein dürfte. Daß die Technologie genial ist,
wenn es denn wirklich funktioniert, steht außer Frage.
Viele Grüße

#9 von Neoe 14.05.02 17:54:52 Beitrag Nr.: 6.404.606 6404606
Dieses Posting: versenden | melden | drucken
kalabrienfan@:
Ich hab schon gedacht , daß man hier mit Qualität gar nicht mehr landen kann. Wenigstens mal ein Mitstreiter. Aber eigentlich müßte diese Aktie recht "trendy" sein. Da GLAXOSMITHKLINE im untenstehenden Artikel ja sogar sagt , daß die Pharmas eigentlich noch gar nicht realisiert haben , um was für eine riesige Sache es sich hier handelt , kann man dem WO-Board eigentlich nicht böse sein.
Bis auf die Tatsache , daß Glaxo hier als Marktführer angesehen wird , finde ich den Artikel ganz gut. Glaxo ist nämlich de facto nicht so weit wie DNAP und GNSC , aber das wissen sie selbst am Besten.


Targeted Therapy Makes a Stand


By Malorye Branca
Bio-IT World

BOSTON (05/07/02)—A series of study results and a new stance by the Food and Drug Administration may provide badly needed fuel for pharmacogenomics. The study of why individuals respond differently to drugs — pharmacogenomics — is one of the most potentially exciting applications of the Human Genome Project. In the not-too-distant future, doctors will be able to use patients` unique genetic profiles to guide treatment decisions, and medicines will be tailored to genetic makeup.

But despite widespread anticipation of the promise of pharmacogenomics, surprisingly few findings to date have supported this view. "There was a big wave of investment in this field awhile ago, and people found it was harder to get results than they thought," says Dennis Henner of MPM Capital.

As a result, the field is losing steam. Some of the smaller pioneering pharmacogenomics companies are anxious to reverse that trend.

Researchers at Genaissance Pharmaceuticals, based in New Haven, Conn., recently reported "statistically significant" relationships between genetic markers and patient responses to cholesterol-lowering drugs, called statins. If confirmed, these relationships could lead to pharmacogenetic tests to determine which drug will work best in a particular patient.

"Number one, it [the study] validates what we are doing, and that we can identify these variations that predict response to therapeutic agents," says Dr. Carol Reed, executive director of medical affairs at Genaissance. "Secondly, the associations are significant."

"Genaissance does not sell any of these drugs, and they are the most successful category of drugs in pharmaceutical history," says Peter Tollman of the Boston Consulting Group. "If these associations are significant enough, this could create a very interesting dynamic. We will see a whole new set of competitors going after the Big Pharma drugs, and a need to respond by Big Pharma."

These results come from an initial analysis of the company`s STRENGTH I (Statin Response Examined by Genetic HAP Markers) study, which involved simvastatin (Merck & Co.`s Zocor); atorvastatin (Pfizer`s Lipitor); and pravastatin (Bristol-Myers Squibb`s Pravachol). The study originally also involved cerivastatin (Bayer`s Baycol), but Genaissance discontinued the Baycol arm of the study when that drug was voluntarily withdrawn from the market last summer after some patients taking it developed potentially fatal side effects. A second study, STRENGTH II, is also nearing completion. It includes the three drugs left in STRENGTH I, as well as lovastatin (Merck`s Mevacor).

The statins represent a huge market. According to IMS Health, Lipitor and Zocor were the second and third top-selling drugs in the world in 2000. IMS recorded almost $16 billion in worldwide sales for cholesterol- and triglyceride-lowering drugs that year.

Statin therapy aims to reduce blood levels of LDL (bad) cholesterol and to improve the ratio of HDL (good) cholesterol to bad. Genaissance has been looking for links between genetic markers and changes in the levels of cholesterol and triglycerides in patients taking these drugs.

Genaissance uses sequencing to find genetic variations called single nucleotide polymorphisms (SNPs) in human DNA. This requires many samples, from the right mix of people, to get a good representation of a target population. The company applies proprietary algorithms to find sets of SNPs, called haplotypes, which are inherited. The goal is to find haplotypes that are "red flags" of disease susceptibility or drug response.

Studying haplotypes, rather than individual SNPs, reduces the number of patients needed for these types of trials because combinations of markers provide a stronger signature than single markers. Genaissance has compiled a database of more than 5,000 such haplotypes, which they call HAP markers. The company has also identified 100 genes that may be linked to patient response to statins.

If further testing confirms the study results, it could lead to products for Genaissance and to better treatment for patients. Tollman, however, advises caution. "The study is small and has other limitations," he says.

In STRENGTH I about 150 patients received each particular type of statin. Overall, more than 500 patients were enrolled. Analysts and researchers are waiting for more details before deciding the study`s importance.

Signs of Hope for Pharmacogenomics?

New studies suggest genetic tests can predict who will do best on therapy using these major drugs. For example, DNAPrint Genomics` study indicated which patients would respond best to Taxol.

Drug Studied/Indication
Source of study
Reference/Date


Estrogen replacement therapy/High cholesterol (cardiovascular disease)
Wake Forest University School of Medicine
New England Journal of Medicine, March 28, 2002


Taxol/Ovarian cancer
DNAPrint Genomics and the University of Miami (Fla.)
Presented at the Society of Gynecological Oncology, March 19, 2002


Statins (Lipitor, Pravachol, Zocor)/High cholesterol
Genaissance Pharmaceuticals
Press release at www.genaissance.com, March 26, 2002


Ziagen/AIDS
Royal Perth Hospital and Murdoch University, Perth, Australia
The Lancet, March 2, 2002

GlaxoSmithKline The Lancet, March 30, 2002



"We did the press release to let the clinical world and investor world know that the study is complete, and that we are analyzing the data, and that there is interesting data there," says Reed, adding that the company plans to publish and present findings from the study throughout the year. (The first presentation was planned for late April, after this issue went to press.) "The study was big enough for us to derive statistically relevant correlations. We expect to derive commercial value from these associations."




FDA`s Positive Position
Perhaps the biggest hurdle to pharmacogenomics has been the perception that the FDA would resist the introduction of these tests. "The FDA never actually said this, but many people believed that the FDA would never allow these types of tests to be approved," says Allen Roses, senior vice president of genetic research at GlaxoSmithKline (GSK), which is a leading player in this field.

But a timely new announcement from the FDA may clear up that perception. "Now the FDA has come out and said, quite dramatically, `Yes, we will look at this,`" says Roses, referring to a recent article in The Pharmacogenomics Journal by Lawrence J. Lesko and Janet Woodcock, two FDA officials. Lesko and Woodcock reported that the FDA has received more than 15 recent applications involving pharmacogenomic tests, and that it is taking steps "to assure that, as a regulatory agency, FDA is prepared to deal with the future influx of [pharmacogenomic data]."

Genaissance`s Reed agrees with Roses about the impact of the article. "This could really change things," she says. With the FDA`s go-ahead, more companies may enter the field, and smaller companies may have less difficulty convincing partners and investors that they can succeed.

With the exception of GSK, leading pharmaceutical companies have been slow in carrying out or funding pharmacogenetic studies of drugs that are already on the market. Last year Jurgen Drews, president of Genaissance and a former president of global research at Roche Pharmaceuticals, was quoted in The Wall Street Journal as saying that pharmaceutical companies were afraid of discovering "the limitations of their drugs."

If pharmacogenetic tests can cause doctors to change prescribing practices, it could erode some drugs` market shares. But it is hard to tell what is keeping Big Pharma away. "I don`t think big companies are trying to delay the development of these tests," says Henner. "The technology just hasn`t yet moved to a point where they see the value of it."

Large pharmas and genomics firms have shown greater interest in applying pharmacogenomics to early-stage drug candidates. By finding out early on that a potential drug has serious side effects in some patients, or by identifying therapies that only work well in a subgroup of people, companies can save on drug development costs. Later, companies may market the therapies and the tests used with them together.

In the meantime, investors may have already grown weary of waiting for results. "Before pharmacogenomics can come into widespread use, these companies will have to show that the data they provide will make a difference to patients, and that doctors can actually use it," say Henner. "Meanwhile, there are a lot of other biotech products that are going to happen much sooner, so that`s where the money is going."




Tide Turning?
During the last few months, there has been a small, but noticeable trickle of results from pharmacogenetic studies (see table). The next step must be to turn these results into actual products.

Early pharmacogenetic tests "looked at extreme responses," says Tony Frudakis, CEO of pharmacogenomics startup DNAPrint Genomics of Sarasota, Fla. "They have looked at too few genes and too few sites in those genes to be useful for more than a very few patients." To become clinically accepted, tests need to work across a wide range of patients. "We are close to this, and Genaissance is close," he says.

DNAPrint recently announced finding genetic markers linked to patient response to paclitaxel (Bristol-Myers Squibb`s Taxol). The company uses an approach similar to that of Genaissance. It hopes to develop a test that will flag those patients who will not have a good response to the drug in order to redirect them to other therapies.

"The answer now relies on how good your informatics are," says Frudakis. "We`re doing complex genetics now, and there are no algorithms out there to do this. You have to develop them yourself."

Even with powerful algorithms, clinical trials cost money. "The big companies should be funding these kinds of studies and making better tools out of these drugs," says Frudakis. "But addressing the current drugs falls on the shoulders of companies like us and Genaissance." Still, Frudakis remains optimistic. "We are writing an NIH grant right now," he says. "If we can get funding, we might have a product on the market in two to three years."

However, GSK`s Roses is skeptical about whether smaller companies can pay for effective pharmacogenomic studies. "We have made a sizable investment in informatics for this, and we are already doing many different clinical studies all the time," says Roses.

GSK, he says, embraced the field early. "We could see that what is good for the patient is good for us," Roses says. Other large pharmaceutical companies may have been slower to climb onboard, he says, because "big pharmas are not mainly R&D organizations; they are sales and marketing organizations, so the people at the top may not fully understand the potential here."

#10 von ZittrigeHand 14.05.02 20:59:01 Beitrag Nr.: 6.406.571 6406571
Dieses Posting: versenden | melden | drucken
hi
bin auch in GNSC.aus irgendwelchen gründen sind sie letzte
woche ziemlich zerschossen wurden.wie NEOE oben berichtete,
immer in 100 trades abgeschossen,dann dicke trades
hinterher.low war bei 1,36..heute momentan bei 1,96 $.
ein schöner anstieg seit freitag.
das einzige was mich bei GNSC stört ist deren informations-
politik,diese lässt zu wünschen übrig.ansonsten halt ich recht viel von denen,die letzten Q`s um 10 % geschlagen,aus-
reichend cash,gutes geschäftsmodel,sowie gute allianzen.
was mir noch postiv auffiel....kein insider(firmenangehöriger)hat trotz des durchaus katastrophalen
charts der letzten monate verkauft.
wollen mal hoffen das sie ihre STRENGTH I ergebnisse was
besser aufschlüsseln,bzw.ihre info-politik verbessern.

gruß
zitter

#11 von Neoe 14.05.02 22:00:46 Beitrag Nr.: 6.407.119 6407119
Dieses Posting: versenden | melden | drucken
Nicht vergessen ZittrigeHand@:
Wie im Artikel gesagt wird , demnächst kommen auch noch die StrenghtII-Resultate.

#12 von ollihat 15.05.02 08:38:11 Beitrag Nr.: 6.409.614 6409614
Dieses Posting: versenden | melden | drucken
GNSC ist bei dem aktuellen Kurs ein aussichtsreiches Investment!

Für mich unverständlich ist die Herunterstufung der Deutschbanker am 29.4. von strong buy auf market perform.
Hat jemand dafür eine Begründung gelesen?

#13 von ZittrigeHand 15.05.02 09:49:06 Beitrag Nr.: 6.410.326 6410326
Dieses Posting: versenden | melden | drucken
jo..olli
die wollten billig rein...lol
na ja,den downgrade hätten die sich sparen können.aktie ist schon vorher ziemlich unter die räder gekommen.

#14 von Neoe 15.05.02 14:02:49 Beitrag Nr.: 6.413.003 6413003
Dieses Posting: versenden | melden | drucken
Die Deutsche Bank ist bereits in GNSC investiert , daß heißt eigentlich grundsätzlich , daß eine Herabstufung Nachkäufe mit sich bringt. Die schneiden sich sicher nicht ins eigene Fleisch , die Welt der Investmentbänker ist ein einziger Sündenpfuhl , nur so langsam durchschaut das glaub ich jeder.

[ZittrigeHand]

yoo....schöner rebound.
über 40% seit dem low zugelegt.wollen mal hoffen das es weiter up geht.
hm..ich sprech zwar ungern KZ`s aus,sollten die märkte sich
wieder erholen und bios sich stabilisiert haben,GNSC`s
strength studies weiterhin positv ausfallen,sollte das KZ
von 10$ bis auf jahressicht drinne sein.

gruß
zitter

[Neoe]

Es geht zwar absolut in die richtige Richtung , aber irgendwie macht mir das Ding Angst. Die Manipulation kennt hier keine Grenzen , aber die Manipulatoren wollen nach oben ,da beklag ich mich mal nicht länger.

[Neoe]

.....in guten wie in schlechten Zeiten; 1,90$.
Das Volumen ist zum Einschlafen. Wenn hier was passiert in den nächsten Tagen ist die Hölle los , sowohl Angebot als auch Nachfrage sind in dieser Preisregion so knapp , daß die Shorties das Ding in den Himmel jagen ,z.B. wenn die StrengthII-Resultate rauskommen.

[ZittrigeHand]

jep
up mit high volumn...down mit low volumn.
die mysteriöseste aktie die ich je im depot hatte

[Neoe]

Nach Tagen der Tristesse kam GNSC heute zurück. Und wie meine Herren.

Nachdem wir noch einmal in die Nähe des Allzeitiefs kamen , wurde innerhalb der letzten Stunde alles aufgekauft , was nicht bei drei auf den Bäumen war. Über die Hälfte des Tagesumsatzes fand in dieser Zeit statt.

Mal abgesehen davon das diese Aktie heillos überverkauft war/ist und die Nasdaq noch ins Plus gedreht hat , denke ich , daß auch die anstehende Entscheidung um die Zulassung des neuen BIOGEN-Medikaments eine Rolle spielen kann.

Diese Entscheidung wird als Wegweiser für die Branche gesehen und als Partner von Biogen kann GNSC natürlich indirekt auch davon profitieren , da Biogen dann in eine rosigere Zukunft schaut , heißt Kohle fließt. Wir wollen ja kein zweites ImClone erleben.


Bei positiver Nasdaq-Entwicklung und positiver Biogen-Entscheidung gebe ich uns morgen zwischen 10 und 20 Prozent plus.

[Neoe]

Jungs , morgen ist Biotechtag. Ich sehe gerade , daß Biogens Medikament zur Zulassung empfohlen wurde. Alle Vorzeichen stehen auf dunkelgrün.

[Neoe]

Vorbörslich steht das BID bereits bei 1,79. Gespannt ob es eine nachhaltige Sache wird. Also zehn Prozent sind es im Moment jedenfalls schon fast.
Genaissance wird wohl in nächster Zeit noch maßgeblich an dem Biogenpräparat Amevive verdienen. Das Medikament ist zwar hochwirksam , fällt aber durch unerwünschte Nebenwirkungen auf. Wer sonst als eine Pharmacogenomics-company wie GNSC sollte den dieses Problem lösen können?

[Neoe]

1,90$

[Neoe]

2,05$=knappe 20 Prozent im Augenblick

[ZittrigeHand]

@ neoe
GNSC strapaziert so ziemlich meine nerven.

[Neoe]

zittrige hand@:
Wem sagst du das. Aber mit dem Biogen-Erfolgserlebnis könnte sich die Situation für die Biotech-Aktien insgesamt erheblich geändert haben. Ich hoffe , daß jetzt auch mal wieder ein größeres Volumen entsteht und die Manipulation damit ein Ende hat. Die Richtung kann eigentlich nur Norden sein.

[Neoe]

Spätestens bis 14.Juni passiert wieder was. Dann findet die lange angekündigte Konferenz statt: The 5th Annual Pharmacogenetics And Medecine Lectures. Unter anderem sprechen der CEO von Genaissance und der Direktor des National Human Genome Research Institutes (NIH).Ich denke es werden neue Strength-Daten auf den Tisch kommen und einiges an Bewegung in den Kurs.

http://www.genaissance.com/special_event.html

[ZittrigeHand]

tja...das war wohl nix.GNSC hat gestern bei relativ high volumn auf ATL geschlossen.
situation scheint hoffnungslos.......

gruß
zitter

[Neoe]

Zittrige Hand@:
Ich denke wir werden nicht enttäuscht , aber die Achterbahnfahrt geht natürlich ziemlich an die Nerven. Bei diesem mickrigen Volumen ist es natürlich schlecht , wenn wirklich jemand seine Bestände verringert. Ich setze wie bisher auf die Manipulatoren und denke , daß sie uns wieder auf die 2$-Marke zurückbringen.

[Neoe]

Yale University and Genaissance Pharmaceuticals Co-sponsor Conference on Pharmacogenetics: New Directions in Genome Research

NEW HAVEN, Conn., June 4 /PRNewswire-FirstCall/ -- Yale University School of Medicine and Genaissance Pharmaceuticals, Inc. invite you to attend:


The Fifth Annual Pharmacogenetics and Medicine Lectures

Friday, June 14, 2002
8:30 AM - 12:30 PM

Yale University School of Medicine
Harkness Auditorium
333 Cedar Street
New Haven, CT 06510

Register at http://www.genaissance.com
or
Call Deborah Lewis at 203-786-3528

No registration fee is required

The program includes:

* Francis S. Collins, M.D., Ph.D., Director, National Human Genome
Research Institute, NIH:
"What Next After the Completion of the Sequencing of the Human
Genome?"
* Keith A. Joiner, M.D., Ph.D., Professor of Medicine, Cell Biology and
Epidemiology, Chief, Section of Infectious Diseases, Director,
Investigative Medicine Program, Yale University School of Medicine:
"Pathogen Diets: What Can We Learn From Genome Sequences to Develop
Unique Therapeutic Opportunities?"
* Anil K. Malhotra, M.D., Associate Director, Psychiatry Research, The
Zucker Hillside Hospital, Associate Professor of Psychiatry, Albert
Einstein College of Medicine:
"Pharmacogenetics in Schizophrenia"
* Alan R. Tall, M.D., Head of the Division of Molecular Medicine and
Specialized Center of Research in Molecular Medicine and
Arteriosclerosis, Columbia University:
"Genomics and Cardiovascular Disease"
* Gualberto Ruano, M.D., Ph.D., Chief Executive Officer, Genaissance
Pharmaceuticals, Inc.:
"The Why, When and How of Pharmacogenetics in Medicine"


Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company also has identified candidates for development in its own pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut.

Contact:
Jacqueline Weaver Anita Kaul, Ph.D.
Yale Public Affairs Office Genaissance Pharmaceuticals, Inc.
203.432.8555 203.786.3439
http://www.yale.edu/opa [e-mail]

[Neoe]

ZittrigeHand@:
Heute schon wieder eine Ankündigung für die Freitagskonferenz. Man könnte fast meinen , da kommt was tolles auf uns zu !?!






Dr. Francis S. Collins, Director, National Human Genome Research Institute, To Deliver Keynote Address at Annual Pharmacogenetics and Medicine Lectures

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ - Yale University School of Medicine and Genaissance Pharmaceuticals, Inc. invite you to attend:

The Fifth Annual Pharmacogenetics and Medicine Lectures

Friday, June 14, 2002
9:00 AM - 12:30 PM

Yale University School of Medicine
Harkness Auditorium
333 Cedar Street
New Haven, CT 06510

Register at http://www.genaissance.com
or
Call Deborah Lewis at 203-786-3528

The event will be broadcast live over the web at http://www.genaissance.com

The program includes:

* Francis S. Collins, M.D., Ph.D., Director, National Human Genome
Research Institute, NIH:
"What Next After the Completion of the Sequencing of the Human Genome?"
* Keith A. Joiner, M.D., Ph.D., Professor of Medicine, Cell Biology and
Epidemiology, Chief, Section of Infectious Diseases, Director,
Investigative Medicine Program, Yale University School of Medicine:
"Pathogen Diets: What Can We Learn From Genome Sequences to Develop
Unique Therapeutic Opportunities?"
* Anil K. Malhotra, M.D., Associate Director, Psychiatry Research, The
Zucker Hillside Hospital, Associate Professor of Psychiatry, Albert
Einstein College of Medicine:
"Pharmacogenetics in Schizophrenia"
* Alan R. Tall, M.D., Head of the Division of Molecular Medicine and
Specialized Center of Research in Molecular Medicine and
Arteriosclerosis, Columbia University: "Genomics and Cardiovascular
Disease"
* Gualberto Ruano, M.D., Ph.D., Chief Executive Officer, Genaissance
Pharmaceuticals, Inc.:
"The Why, When and How of Pharmacogenetics in Medicine"


Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company also has identified candidates for development in its own pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut

[ZittrigeHand]

moin neoe

wollen mal hoffen das positives dabei rauskommt.
GNSC scheint sich ja,wenn auch auf low volumn,stabilisiert zu haben.

gruß
zitter

[Neoe]

Genaissance Pharmaceuticals Announces Management Appointments

- New Positions Reflect Focus on Commercialization -

NEW HAVEN, Conn., July 2/PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC), the leader in applying genomic variation to the development and marketing of medicines, today announced that Kevin Rakin, President of Genaissance Pharmaceuticals, has assumed the additional position of Chief Operating Officer, and Joseph Keyes has been promoted to Vice President and Chief Financial Officer. Mr. Rakin previously held the position of Chief Financial Officer.

Mr. Rakin, 41, has been responsible for the Company`s financing, business development activities and investor relations. Highlights of his tenure include raising $150 million in public and private funds and leading a business development team which has negotiated the Company`s corporate collaborations with AstraZeneca, Biogen, Johnson & Johnson and Pfizer. The newly created position of Chief Operating Officer reflects the importance that Genaissance is placing on executing its business plan of establishing additional corporate collaborations, and forming joint ventures and marketing alliances to generate a balanced portfolio of royalty-bearing agreements for pharmaceutical products. The Company`s goal is to continue to grow its base of revenues while reducing its overall operating expenses.

"I am pleased that Genaissance has reached this point of commercial maturation where we can aggressively advance our discoveries in the genetics of drug response and translate them into important new pharmaceutical and diagnostic products," said Gualberto Ruano, M.D., Ph.D., CEO of Genaissance. "I congratulate Kevin as he assumes these additional duties to develop new business opportunities and bring our proprietary gene variation technology to companies in the healthcare industry."

Jurgen Drews, M.D., Chairman of Genaissance added, "The Board of Directors recognizes that Genaissance is transitioning to a company that is commercializing its leadership position in a receptive market for pharmacogenomics. We believe Kevin`s efforts should be focused on the on-going development of commercial opportunities and implementation of the Company`s business model. We are confident in the talent Genaissance has assembled and believe that Kevin and his team are well positioned to build on the momentum established to date, such as the agreements with top-tier biopharmaceutical companies and a major reduction in expenses over the past two quarters."

Mr. Keyes, 44, joined Genaissance in March 2001 as Executive Director, Finance. Mr. Keyes is a Certified Public Accountant and brings to Genaissance over 20 years of financial experience. Prior to joining Genaissance, Mr. Keyes was Vice President, Finance for DSL.net, Inc., a public company that provides high-speed data communications and Internet access. Prior to DSL.net, he was CFO for Heritage Consumer Products, and spent seven years at United States Surgical Corporation as Head of Budgeting and Planning, and as a Group Controller. He began his career at Price Waterhouse, where he spent 12 years.

"During the past year, Joe has been instrumental in leading our fiscal planning, particularly in the prudent management of our resources," said Kevin Rakin. "We currently have more than two years of cash available to fund our expected net losses, debt obligations and capital expenditures. Joe`s experience with growth companies will help us to plan appropriately as we continue to build upon our base business."

Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company also has identified candidates for development in its own pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut. Please visit http://www.genaissance.com for additional information

[derschweizer]

Genaissance wurde wie alle Bio`s richtig verprügelt !
Jetzt scheint mir der Boden erreicht.
Die Chance überwiegt bei weitem das Risiko, jetzt noch super günstig einzusteigen !
Cash ca. 42 Mio.$
Marktkap. 22 Mio.
Share price 0,98 $
Die Bewertung ist lächerlich niedrig, jegliche Fantasie scheint für immer gestorben zu sein !
Werde meine Genaissance aufstocken und Sie die nächsten drei Jahre im Safe deponieren !

[ZittrigeHand]

holla
GNSC sieht ja nur noch schei...aus.
wollen mal die kommenden Q`s abwarten und hoffen das das teil über die 1 $ geht(wg.delisting).
a´nsonsten...wie immer zu bemängeln.....die informationspolitik von GNSC.

gruß
zitter

[Neoe]

Wenn ich nicht schon alles verbraten hätte , würde ich mich dem Schweizer gerne anschließen , aber andererseits: Weitere Verluste sind derzeit immer möglich. Man muß sich seine Schäfchen einfach aussuchen, auf den eigenen Verstand setzen und darf sich von den aalglatten Schweinen , die von dem schlechten Markt noch weiter profitieren möchten , nicht ins Boxhorn jagen lassen.

Z.H.@: Hold on , wir werden bei den Gewinnern sein.

[Neoe]

ZittrigeHand@:

Hoffe , daß du noch dabei bist, die Sache wird rund. Nächstes Jahr liegt der Cashburn nur noch bei rund 16 Millionen bei 30 Millionen Cash zum Jahresende. Die Bestätigung , das GNSC an einem Diagnostikkit für Amevive arbeitet liegt auch vor.
Einnahmen daraus , können 2004 zwischen 2,5 und 25 Millionen Dollar betragen. Bis dahin stellt Biogen Kapital zur Forschung zur Verfügung , das heißt , die korrigierten Zahlen sollten zumindest erreicht werden.

2005 will GNSC profitabel sein , benötigt dazu aber nur noch ein jährliches Umsatzwachstum von ca. 20 Prozent.
Bisher , wie du ja weißt: von 2000 auf 2001 ca. 1000% , von 2001 auf 2002 ca. 100%.

Man erwartet in diesem Jahr mindestens! noch eine neue Partnerschaft und hat noch einiges für nächstes Jahr in der Pipeline.

Die StrengthI-Daten waren wohl doch nicht so schlecht , wie allgemein bemängelt. Auch hier verhandelt man bereits.

J&J und GNSC haben anscheinend einen Durchbruch gelandet und GNSC hofft das jetzt die Entscheidung zur Medikamententwicklung folgt.

Kursziel dausend und wo Gurken wir rum. Ich glaub ich versteh die Börse nicht mehr.

[Neoe]

Die ganzen Infos sind übrigens unter foldenden Adressen abzurufen , also es gibt noch keine ad-hocs diesbezüglich:

http://www.informedinvestors.com/iif_forums/forum.cfm?forumI…

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=GNSC&…

[Neoe]

SORRY , VORHER DEN ALTEN THREAD AUSGEGRABEN

Bin wirklich gespannt , was Q3 gebracht hat. Alles was über 1,9 Millionen Dollar an Einnahmen liegt , kommt von Biogen und es wäre ein mehr als gutes Zeichen , zumindest für mich,
wenn die Zusammenarbeit endlich auch was abwirft.


Genaissance Pharmaceuticals, Inc. Invites You to Participate in its Third Quarter 2002 Conference Call

New Haven, CT, November 5, 2002 – In conjunction with the release of its financial results for the third quarter ended September 30, 2002, management of Genaissance Pharmaceuticals (Nasdaq: GNSC), will conduct a conference call:

Tuesday, November 12, 2002
11:00 a.m. Eastern

To participate in this call,
dial: 913-981-5522
confirmation code: 716060
shortly before 11:00 a.m. Eastern

To reserve a line,
please call Rhonda Chiger at Rx Communications Group, LLC
917-322-2569.

A replay of the call will be available from 2:00 p.m. Eastern through midnight Monday, November 18th, 2002. The replay number is 719-457-0820, confirmation code 716060 Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut.

[Neoe]

Noch was Interessantes:

GNSC arbeitet ja erwiesenermaßen mit Astra Zeneca zusammen und will demnächst auf dem Gebiet der Cholesterinsenkung ein Diagnostik-Kit anbieten ; GNSC hat außerdem einen Interessenten dafür erwähnt (Conference-Links vom 27.10.02 geben darüber mehr Auskunft).Nun einmal folgende Meldung von Astra Zeneca:
..........................................................
Der britische Pharmakonzern AstraZeneca Plc. präsentierte auf dem Cardiology Meeting in Berlin neue Daten für seinen experimentellen Cholesterin-Senker Crestor. Demnach ist das Arzneimittel wirkungsvoller als Lipitor von Pfizer und zeigt eine um 8,4 Prozent deutlichere Verringerung des Cholesterins.

Die U.S. Food and Drug Administration will das Medikament zum Handel zulassen, fordert jedoch zuvor weitere Informationen. AstraZeneca beabsichtigt, im ersten Quartal 2003 neue klinische Daten vorzulegen, um im dritten oder vierten Quartal 2003 mit der Markteinführung zu beginnen.
............................................................


Weitere Daten heißt , daß Nebenwirkungen bei den Patienten aufgetreten sind (die gute Wirkung ist ja bereits erwießen) , was GNSC mit seinen HAPs und dem Kit ins Spiel bringt.

Ich erinnere nur an Biogen , die sogar noch nach der Zulassung von Amevive mit GNSC an diesem Medikament arbeiten , wegen vieler unerwüschter Nebenwirkungen , was im Jahre 2004 zu einem Diagnostik-Kit führen wird.

Im Falle von Astra Z. sind wir ja sogar noch im Stadium der Zulassung , was die Kooperationsbereitschaft und Interesse noch mal potenzieren sollte.

Fazit:
GNSC ist im Moment ein Puzzle , dessen Teile in alle vier Himmelsrichtungen zerstreut wurden , aber wehe man schafft es das Bild zusammenzusetzen.
Neben eigenentwickelten Medikamenten werden wir schon in wenigen Jahren eine zentrale Rolle in vielen Zulassungsverfahren spielen , da die FDA aufgrund der Billigmedikamente aus Indien und anderswo , die Kriterien verschärfen wird müssen , sonst gehen ihre Flaggschiffe , wie z.B. Pfizer , vor die Hunde.
Noch wollen die BigCaps das selbst nicht wahrhaben , aber die gezielte Verschreibung von Medikamenten aufgrund der genetischen Beschaffenheit des Patienten wird sie vor ihrem Untergang retten , obwohl sie die Pharmacogenomicsunternhemen derzeit noch als eine Art Wolf im Schafspelz ansehen.

Die Zukunft sieht so aus:
Viele Medikamente , kleine Zielgruppen , sehr hohe Wirksamkeit , keine Nebenwirkungen.

[Neoe]

Mit diesen Zahlen im Gepäck muß man dem Management unumwunden totales Versagen attestieren.

Jetzt sind sogar noch die revidierten Ziele in Gefahr , obwohl ich natürlich nicht weiß , welchen prozentualen Anteil Q4 am Gesamtumsatz haben soll.

Bleibt nur zu hoffen , daß sie im Conference Call auch mal was überraschend Positives zu berichten haben , sonst geht es wohl wieder rückwärts.


Hier die Katastrophe in Wort und Zahl:



Genaissance Pharmaceuticals Reports Third Quarter and Nine Month Results

- Revenues Increase Year Over Year -

- Operating Expenses and Burn Rate Reduced through Implementation of Cost
Savings and Restructuring Program -

NEW HAVEN, Conn., Nov. 12 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today reported its financial results for the third quarter and nine months ended September 30, 2002. Financial Results

For the quarter ended September 30, 2002, revenue increased 62% to $1.8 million from $1.1 million for the third quarter of 2001. Operating expenses for the quarter were $6.7 million, of which $4.8 million were attributable to research and development. This reduction in operating expenses represents a 57% decrease compared to the same period last year and a 27% decrease compared to the second quarter, excluding the second quarter charge related to the impairment of certain fixed assets. The continued decrease in expenditures reflects the implementation of the Company`s cost savings and restructuring program announced in August.

Genaissance reported a net loss for the quarter of $5.2 million or $0.23 per share compared to a net loss of $11.8 million or $0.52 per share for the third quarter last year.

Revenue for the nine months ended September 30, 2002 increased 76% to $5.5 million from $3.1 million for the same period last year. Operating expenses for the first nine months of 2002, decreased 25% to $32.6 million from $43.3 million for the same period last year; this includes a non-recurring charge of $6 million related to the impairment of certain fixed assets in the second quarter of 2002. Operating expenses for the first nine months, before the non-recurring charge, were $26.6 million, a 39% decrease from the same period last year. Research and development expenses for the nine months ended September 30, 2002 were $19.6 million, a 43% decrease compared to research and development expenses of $34.0 million for the nine months ended September 30, 2001. The decrease in research and development expenses is primarily due to decreased spending on clinical trials, reagents, payroll and other general expenditures, resulting from the Company`s cost savings and restructuring program.

Genaissance reported a net loss, including the non-recurring charge, for the nine months ended September 30, 2002 of $27.7 million or $1.22 per share as compared to a net loss of $36.2 million or $1.59 per share for the same period in 2001. The net loss for the nine months ended September 30, 2002, before the non-recurring charge, was $21.7 million or $0.95 per share.

As of September 30, 2002, Genaissance had cash, cash equivalents and marketable securities totaling $36.4 million. Cost Savings and Restructuring

On August 5, 2002, the Company announced a restructuring program, including the promotion of Kevin Rakin to President and CEO; the reduction of its workforce by 20%, mainly in DNA sequencing and related informatics support; and a decision to seek partners for all internal product development programs. Genaissance has also taken steps to develop additional business opportunities for its technology, including the recruitment of sales personnel; leveraging its existing infrastructure to attract additional business and new corporate partners; and the refinement of its marketing message. In his new role as Chief Scientific Officer, Gualberto Ruano, M.D., Ph.D., is focusing on developing new markets for Genaissance technology, including bio-defense and other government-sponsored initiatives.

"We believe that our level of expenses, our management focus and our cash resources are now aligned with our core expertise of associating gene variation with drug response in order to improve drug efficacy and safety," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "In addition, the recent announcement about the International HapMap Project reinforces our approach in using haplotypes. Our experience in generating meaningful associations for the development of novel therapeutic and diagnostic products provides us with a strong leadership position that we fully intend to leverage."

Genaissance will host a conference call to review the matters discussed in this press release. The conference call will take place today at 11:00 am, Eastern Standard Time. The dial-in number for the third quarter conference call is [phone], and the confirmation code is 716060. A replay of the call will be available from 2:00 pm, Eastern Standard Time, today through midnight Monday, November 18th. The replay can be accessed by dialing [phone], confirmation code 716060.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance currently has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to decrease expenses, align costs with its revised business plan, apply its technologies to the development, marketing and prescribing of drugs and leverage its existing infrastructure to attract additional business and new corporate partners. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2002 filed with the Securities and Exchange Commission on August 14, 2002. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

Contact:

Kevin Rakin Joseph Keyes
President & Chief Executive Officer Chief Financial Officer
Genaissance Pharmaceuticals, Inc. Genaissance Pharmaceuticals, Inc.
203.786.3404 203.786.3674
[e-mail] [e-mail]

Rhonda Chiger (investors)
Rx Communications
917.322.2569
[e-mail]

GENAISSANCE PHARMACEUTICALS, INC.

Statements of Operations
(Unaudited)
(In thousands, except per share data)

Three Months Ended Nine Months Ended
September 30, September 30,
2002 2001 2002 2001

License and service
revenue $1,754 $1,083 $5,539 $3,149

Operating Expenses:
Research and
development 4,767 12,637 19,557 34,046
General and
administrative 2,001 2,896 6,930 8,901
Stock based
compensation (100) 96 107 381
Impairment of fixed
assets -- -- 6,000 --

Total operating
expenses 6,668 15,629 32,594 43,328

Loss from operations (4,914) (14,546) (27,055) (40,179)

Interest income
(expense), net (268) 171 (651) 1,403
Income tax (expense)/
benefit (28) 2,574 (28) 2,574

Net loss attributable to
common stockholders $(5,210) $(11,801) (27,734) (36,202)

Net loss per common
share, basic and
diluted $(0.23) $(0.52) (1.22) (1.59)

Weighted average shares
used in computing
Net loss per
common share 22,827 22,773 22,802 22,746


Balance Sheet Data
(in thousands)
(unaudited)

Sept. 30, Dec. 31,
2002 2001

Cash, cash equivalents and marketable
securities $36,355 $59,673
Working capital 24,879 47,775
Total assets 54,669 92,277
Long & Short Term debt and capital leases 16,603 22,194
Stockholders` equity 31,310 58,979

[ZittrigeHand]

katastrophe

gut für 100 % in den letzten tagen *lol*

[Neoe]

Tja , Zittrige Hand@:

Wie meistens passiert an der Börse ja exakt das was man nicht erwartet und wir dürfen uns heute über 10% freuen.
Wenn man auf die Revenues schaut , hätten sie eigentlich gnadenlos abgestraft werden müssen.

Allerdings hat man jetzt zumindest bewiesen , daß man die Kosten einigermaßen in den Griff bekommt.
Was auf dem Conference C. gesagt wurde , habe ich leider verpasst. Mal sehen , wo man den nochmal zu hören bekommt.

Obwohl ich rote Vorzeichen erwartete , bin ich natürlich jetzt ganz zufrieden.

[ZittrigeHand]

Financial Results

For the quarter ended September 30, 2002, revenue increased 62% to $1.8 million from $1.1 million for the third quarter of 2001. Operating expenses for the quarter were $6.7 million, of which $4.8 million were attributable to research and development. This reduction in operating expenses represents a 57% decrease compared to the same period last year and a 27% decrease compared to the second quarter, excluding the second quarter charge related to the impairment of certain fixed assets. The continued decrease in expenditures reflects the implementation of the Company`s cost savings and restructuring program announced in August.

Genaissance reported a net loss for the quarter of $5.2 million or $0.23 per share compared to a net loss of $11.8 million or $0.52 per share for the third quarter last year.

Revenue for the nine months ended September 30, 2002 increased 76% to $5.5 million from $3.1 million for the same period last year. Operating expenses for the first nine months of 2002, decreased 25% to $32.6 million from $43.3 million for the same period last year; this includes a non-recurring charge of $6 million related to the impairment of certain fixed assets in the second quarter of 2002. Operating expenses for the first nine months, before the non-recurring charge, were $26.6 million, a 39% decrease from the same period last year. Research and development expenses for the nine months ended September 30, 2002 were $19.6 million, a 43% decrease compared to research and development expenses of $34.0 million for the nine months ended September 30, 2001. The decrease in research and development expenses is primarily due to decreased spending on clinical trials, reagents, payroll and other general expenditures, resulting from the Company`s cost savings and restructuring program.

Genaissance reported a net loss, including the non-recurring charge, for the nine months ended September 30, 2002 of $27.7 million or $1.22 per share as compared to a net loss of $36.2 million or $1.59 per share for the same period in 2001. The net loss for the nine months ended September 30, 2002, before the non-recurring charge, was $21.7 million or $0.95 per share.

As of September 30, 2002, Genaissance had cash, cash equivalents and marketable securities totaling $36.4 million.

Cost Savings and Restructuring

On August 5, 2002, the Company announced a restructuring program, including the promotion of Kevin Rakin to President and CEO; the reduction of its workforce by 20%, mainly in DNA sequencing and related informatics support; and a decision to seek partners for all internal product development programs. Genaissance has also taken steps to develop additional business opportunities for its technology, including the recruitment of sales personnel; leveraging its existing infrastructure to attract additional business and new corporate partners; and the refinement of its marketing message. In his new role as Chief Scientific Officer, Gualberto Ruano, M.D., Ph.D., is focusing on developing new markets for Genaissance technology, including bio-defense and other government-sponsored initiatives.

"We believe that our level of expenses, our management focus and our cash resources are now aligned with our core expertise of associating gene variation with drug response in order to improve drug efficacy and safety," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "In addition, the recent announcement about the International HapMap Project reinforces our approach in using haplotypes. Our experience in generating meaningful associations for the development of novel therapeutic and diagnostic products provides us with a strong leadership position that we fully intend to leverage."

Genaissance will host a conference call to review the matters discussed in this press release. The conference call will take place today at 11:00 am, Eastern Standard Time. The dial-in number for the third quarter conference call is [phone], and the confirmation code is 716060. A replay of the call will be available from 2:00 pm, Eastern Standard Time, today through midnight Monday, November 18th. The replay can be accessed by dialing [phone], confirmation code 716060.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance currently has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to decrease expenses, align costs with its revised business plan, apply its technologies to the development, marketing and prescribing of drugs and leverage its existing infrastructure to attract additional business and new corporate partners. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2002 filed with the Securities and Exchange Commission on August 14, 2002. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

Contact:

Kevin Rakin Joseph Keyes
President & Chief Executive Officer Chief Financial Officer
Genaissance Pharmaceuticals, Inc. Genaissance Pharmaceuticals, Inc.
203.786.3404 203.786.3674
[e-mail] [e-mail]

Rhonda Chiger (investors)
Rx Communications
917.322.2569
[e-mail]

GENAISSANCE PHARMACEUTICALS, INC.

Statements of Operations
(Unaudited)
(In thousands, except per share data)

Three Months Ended Nine Months Ended
September 30, September 30,
2002 2001 2002 2001

License and service
revenue $1,754 $1,083 $5,539 $3,149

Operating Expenses:
Research and
development 4,767 12,637 19,557 34,046
General and
administrative 2,001 2,896 6,930 8,901
Stock based
compensation (100) 96 107 381
Impairment of fixed
assets -- -- 6,000 --

Total operating
expenses 6,668 15,629 32,594 43,328

Loss from operations (4,914) (14,546) (27,055) (40,179)

Interest income
(expense), net (268) 171 (651) 1,403
Income tax (expense)/
benefit (28) 2,574 (28) 2,574

Net loss attributable to
common stockholders $(5,210) $(11,801) (27,734) (36,202)

Net loss per common
share, basic and
diluted $(0.23) $(0.52) (1.22) (1.59)

Weighted average shares
used in computing
Net loss per
common share 22,827 22,773 22,802 22,746


Balance Sheet Data
(in thousands)
(unaudited)

Sept. 30, Dec. 31,
2002 2001

Cash, cash equivalents and marketable
securities $36,355 $59,673
Working capital 24,879 47,775
Total assets 54,669 92,277
Long & Short Term debt and capital leases 16,603 22,194
Stockholders` equity 31,310 58,979


Make Your Opinion Count - Click Here




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.

[ZittrigeHand]

I am sending you a statement that we have prepared regarding our listing on the Nasdaq. I hope that this information answers your question and addresses your concerns.

As was publicly disclosed in the third quarter 10-Q filing, Genaissance received a letter from the Nasdaq National Stock Market regarding its lack of compliance with the $1 minimum stock price rule. The Company has until December 18th to comply with this rule.

Genaissance is committed to providing a stable trading environment for the Company`s stock. If the closing bid price of Genaissance`s stock is not at least $1.00 for a minimum of 10 days, there are several options that the Nasdaq Stock Market makes available to companies in a similar position as outlined below.

Genaissance has the ability, with specific requirements, to trade on the Nasdaq SmallCap Stock Market until at least September 15, 2003. If the closing bid price for Genaissance`s stock reaches $1.00 for either 10 consecutive days before March 18, 2003 or for 30 consecutive days afterwards, Genaissance would return to trading on the Nasdaq National Stock Market. Genaissance believes that it satisfies the criteria required for transfer to the Nasdaq SmallCap Stock Market and for continued trading on the Nasdaq SmallCap Stock Market through September 15, 2003.

Should the Company list on the Nasdaq SmallCap Stock Market, Genaissance shareholders will still be able to trade the Company`s stock in the same manner as they do now. Information about the Company`s stock price will still be found in many newspapers, such as the Wall Street Journal, and on the Internet. Genaissance`s ticker will remain GNSC.

Genaissance believes that the options outlined above will keep the Company in a stable trading environment for a reasonable period of time while Genaissance implements its focused business plan to create value that will be recognized by the marketplace. As was announced in August, Genaissance restructured its business, reducing its workforce by 20%. The Company is seeking partners for all of its internal product development programs and has taken steps to develop additional business opportunities for Genaissance`s technology by leveraging the existing infrastructure to attract additional business and new corporate partners. This restructuring has already resulted in a lowering of expenditures by 57% compared to last year. Our cash position as of September 30th was $36.3 million, which we believe, with a minimum annual increase in revenues of 25 to 30 percent, is sufficient to reach financial breakeven in 2005.

There is no doubt that Genaissance is operating in a volatile market environment, but the Company believes that it has made the necessary tough decisions and put in place a strategy for growth.


Gerald F. Vovis, Ph.D.
Executive Vice President
Chief Technology Officer
Genaissance Pharmaceuticals, Inc.
telephone: [phone]
facsimile: 203-492-4475
[e-mail]


entweder geht GNSC den bach runter,oder sie schaffen es wirklich

[Neoe]

Danke für deine Info Zittrige Hand.

Das abschließende Fazit kommt übrigens sehr geil:

"entweder geht GNSC den bach runter,oder sie schaffen es wirklich"

[ZittrigeHand]

aah...ich vergaß
eine dritte möglichkeit wäre auch noch gegeben.
übernahme.....portokasse für die big players

[ZittrigeHand]

[Neoe]

Hab es auch bemerkt , mal sehen , ob endlich was fundamentales kommt.
Falls nicht wäre ich trotzdem schon glücklich , wenn wir über einem Dollar schließen. Dann wäre die Delisting-Angst erst mal vom Tisch.

[Neoe]

Wir haben bei einem Dollar geschlossen , es geht bergauf.

[Max1973]

Servus Neoe,


ich hab sie ab heute auch auf der Watchlist.
Aktuell 0,89$

mfg
Max

[ZittrigeHand]

Press Release Source: Genaissance Pharmaceuticals, Inc.


Genaissance Pharmaceuticals Achieves a Milestone in Pharmacogenetics Alliance With Johnson & Johnson Pharmaceutical Research & Development
Thursday December 5, 8:38 am ET


NEW HAVEN, Conn., Dec. 5 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has reached a milestone in its pharmacogenetics-based alliance with Johnson & Johnson Pharmaceutical Research & Development, division of Janssen Pharmaceutica, N.V. (J&JPRD). Genaissance will grant certain rights to J&JPRD related to this event and J&JPRD will make a payment to Genaissance in recognition of those rights payable prior to December 31, 2002.
"This milestone demonstrates that our HAP(TM) Technology can be used to identify meaningful associations between genetic variation and clinical observations," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We are pleased with the close and productive working relationship we have with our colleagues at Johnson & Johnson Pharmaceutical Research & Development and look forward to continuing to work closely together to further integrate the results generated from our alliance into pharmaceutical product development."

Formed in November 2000, the multi-year agreement with J&JPRD covers the discovery, development and commercial applications of Genaissance HAP(TM) Technology. Under the terms of the agreement, J&JPRD gained a license to the Genaissance HAP(TM) Technology platform. In addition, Genaissance reserved genotyping capacity in its HAP(TM) Typing facility to assist J&JPRD in the determination of HAP(TM) Markers in clinical trial samples.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance currently has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson PRD, and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to decrease expenses, align costs with its revised business plan, apply its technologies to the development, marketing and prescribing of drugs and leverage its existing infrastructure to attract additional business and new corporate partners. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Reports on Form 10-Q for the quarter ended June 30, 2002 and September 30, 2002 filed with the Securities and Exchange Commission on August 14, 2002 and November 14, 2002, respectively. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

Contact:

Kevin Rakin Rhonda Chiger (investors)
President & Chief Executive Officer Rx Communications
Genaissance Pharmaceuticals, Inc. 917.322.2569
203.786.3404 [e-mail]
[e-mail]




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.

[Max1973]

ein paar andere wohl auch,

in Frankfurt 1,15€

[ZittrigeHand]

pffffffffff...NAZ spielt heut nicht mit

na ja...so what !?
milestone zahlung zeigt jedenfalls das ihre technologie wohl
doch zukunft haben wird(wollens hoffen )
würde aber gerne mal die höhe der zahlung wissen

[Neoe]

Die Meilensteinzahlung wird uns wohl zumindest davor bewahren die sowieso gesenkten Umsatzziele zu verpassen.
Ich denke aber , daß wir weitere News sehen werden.
Eine völlig neue Partnerschaft wurde für 3-4 Wochen nach den Q3-Zahlen angekündigt. Das wäre also spätestens Ende nächster Woche fällig.
Zudem wollte man auch mit Biogen vorwärts kommen.

[Neoe]

1,09$ , das heißt auf Tageshoch geschlossen. Die Spannung und der Kurs steigen weiter.

[ZittrigeHand]

go,go,go...GNSC

schöner boden

[Neoe]

zittrige hand@:

Scheint als hätten wir die Delistingsorgen (fast) hinter uns gelassen. Nach dem heutigen Tag noch sechs weitere über dem Dollar und wir sind wieder ein sicheres Nasdaq-Mitglied.

Scheint als würde Genaissance tatsächlich eine Weihnachtsbescherung planen.

[ZittrigeHand]

Reuters
GE Capital claims Genaissance defaults on lease
Monday December 16, 5:32 pm ET


NEW HAVEN, Conn., Dec 16 (Reuters) - Genaissance Pharmaceuticals Inc. said on Monday GE Capital Corp. seeking $3.9 million immediately from the biotechnology company, claiming it defaulted on a lease.
ADVERTISEMENT


GE Capital, a unit of General Electric Co. (NYSE:GE - News), claims the default in the lease came from an alleged material adverse change in Genaissance -- something the company denies.

The allegation of a default led to a cross-default under an agreement with Finova, but that default claim is suspended until late January 2003, or resolution of the GE Capital claim, Genaissance said.

Genaissance intends to defend itself from GE Capital`s claims. GE capital filed a complaint in the Superior Court of the State of Connecticut, seeking payment for all amounts due under the lease signed April 10, 1999.

Genaissance, which uses the study of human gene variation to develop medicines, said has and will continue to pay all of the Company`s debt obligations. Genaissance currently owes its lease creditors a total of about $10.4 million of principal and interest, most of which is scheduled for payment in fiscal 2003.

[ZittrigeHand]

NEW HAVEN, Conn., Dec. 17 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has entered into a pharmacogenomics based agreement with Pharmacia Corporation (NYSE: PHA - News). Genaissance will apply its HAP(TM) Technology to clinical trial samples from Pharmacia. Financial terms of the agreement were not announced.
"We are pleased to add Pharmacia to the growing list of pharmaceutical companies that have chosen Genaissance to provide them with the resources for pharmacogenomics based clinical development, further demonstrating the utility of our technology," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with five major pharmaceutical and biotechnology companies: AstraZeneca, Biogen, Johnson & Johnson, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to decrease expenses, align costs with its revised business plan, apply its technologies to the development, marketing and prescribing of drugs and leverage its existing infrastructure to attract additional business and new corporate partners. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Reports on Form 10-Q for the quarter ended June 30, 2002 and September 30, 2002 filed with the Securities and Exchange Commission on August 14, 2002 and November 14, 2002, respectively. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

Contact:

Kevin Rakin Rhonda Chiger (investors)
President & Chief Executive Officer Rx Communications
Genaissance Pharmaceuticals, Inc. 917.322.2569
203.786.3404 [e-mail]
[e-mail]

[Neoe]

Also wurden die Versprechen, die zuletzt gemacht wurden, alle eingehalten. Sie haben übrigens von mindestens einer neuen Kooperation gesprochen, also die Luft ist noch längst nicht raus.

Mit Pharmacia hat man sich eine weitere Topadresse an Land gezogen. Der Konzern hat einen Jahresumsatz von ca. 15 Milliarden Dollar, da sollte doch auch für uns was abfallen.

P.S.:
Außerdem noch ein weiterer Tag über dem Dollar und wir sind die Delistingsorgen los, GE Capital würde ich für die Scheißmeldung von gestern gerne in die Luft sprengen. Drückt die Daumen, so daß die 1,00 hält.

[ZittrigeHand]

Dow Jones Business News
Stock Rating Reiterations Midday Update: PIR MWY THQI
Tuesday December 17, 12:44 pm ET


Rating reiterations for Dec. 17 from Briefing.com:

Company Symbol Brokerage Firm Reiterations




Genaissance Pharma GNSC Brean Murray Buy





ANALysten kümmern sich noch um GNSC


@neoe

wollen mal hoffen das GNSC über den 18.´hinaus über einen dollar bleibt,bzw.den weg nach oben findet.
wie gewohnt keine finanz.angaben zu o.g.deal

[Neoe]

Die Anhebung des Ratings hinterließ sofort seine Spuren. Exakt zur selben Zeit, begann GNSC wieder zu steigen, seither nur Zukäufe.

Herzlichen Dank Brean Murray!! Wer auch immer ihr seid.

[Neoe]

Die Anhebung des Ratings hinterließ sofort seine Spuren. Exakt zur selben Zeit, begann GNSC wieder zu steigen, seither nur Zukäufe.

Herzlichen Dank Brean Murray!! Wer auch immer ihr seid.

[ZittrigeHand]

Press Release Source: Genaissance Pharmaceuticals, Inc.


Genaissance Regains Full Compliance with Nasdaq National Market Standards
Friday December 20, 12:02 pm ET


NEW HAVEN, Conn., Dec. 20 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has received a letter from Nasdaq stating that Genaissance has regained compliance with the Nasdaq National Market continued listing standards, including the $1.00 closing minimum bid price. Accordingly, Genaissance common stock will continue to trade on the Nasdaq National Market under the symbol GNSC.
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance currently has agreements with five of the top pharmaceutical and biotechnology companies: AstraZeneca, Biogen, Johnson & Johnson PRD, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

[ZittrigeHand]

sieht wieder mal so richtig sche.... aus
von 1,40 $ auf momentan 0,91 $ zurückgefallen.
kaum war die "buy" bewertung raus gings abwärts



Pharmacia is now added to our list.

LICENSEN AND MILESTONE PAYMENTS, RECEIVED FROM LONG TERM CONTRACT WITH:
BIOGEN
JANSSEN RESEARCH (JOHNSON AND JOHNSON)
GENE LOGIC
VISIBLE PRODUCTS
PFZER
ASTRAZENECA
Pharmacia

(GNSC is a whole lot LESS RISKY now, then it ever was when is was an IPO.)


no santa for GNSC

[Neoe]

Gutes neues Jahr an alle GNSC-Fans und Beobachter. Ich glaube 2003 wird ein entscheidendes Jahr werden. Die Weichen sind gestellt.

[Neoe]

Connecticut Business, Industry Gurus Speculate about 2003 Economy

HARTFORD, Conn., Jan 05, 2003 (Connecticut Post - Knight Ridder/Tribune Business News via COMTEX) -- Biotechnology is expected to be a rising star in the state`s economy this year, while the general field of information technology faces brutal prospects, according to representatives of both sectors. The predictions came Friday during a discussion at the Connecticut Business & Industry Association`s Economic Summit and Outlook at the Hilton. Kevin Rakin of Genaissance Pharmaceuticals Inc. and Kevin Donohue of Greywolf Technologies discussed the diverging fortunes of their respective businesses.

Rakin, president and chief executive officer of New Haven-based Genaissance, said biotechnology could be a driving force in the national and state economy in 2003. Genaissance develops new tests for drugs based on genomic research and also develops marketing and prescription campaigns. From 1992 to 2001, investment in biotechnology rose from $7 billion to $30 billion nationwide, according to Rakin. He said that trend would most likely continue as the $300 billion pharmaceutical industry looks to cut in-house research costs and partner with emerging biotechnology companies. Pharmaceutical companies, he said, need to produce three new drugs a year to meet profit projections.

The industry will continue to prosper, according to Rakin, because the early research and development stage for new drugs is cost prohibitive. Universities, such as New Haven`s Yale, are able to get grants to study and develop new drugs and then spin off biotech companies, which in turn partner with pharmaceutical companies to develop a new drug for the market. Rakin pointed out that, in a single year, Yale received $240 million in grants from the federal government for health research, a figure only $10 million behind Harvard in total grants. The two universities will help secure New England`s place in the industry because of the amount of funding the schools attract, Rakin said.

He also noted that, despite the high cost of living in Connecticut, it is cheaper than living around Boston and said he expects the New Haven area to lead the state in the industry.


Unser CEO scheint guter Dinge zu sein.

[Neoe]

Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Millennium Pharmaceuticals


NEW HAVEN, Conn., Jan 7, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genaissance
Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has licensed its
HAP(TM) Technology to Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) for use in
its drug discovery and development programs. Under the terms of the
non-exclusive, multi-year agreement, Millennium will pay Genaissance license
fees. Genaissance will have certain rights to support Millennium`s DNA biomarker
and pharmacogenomic efforts.

"We are pleased to enter into this agreement with Millennium, as they have a
track record of using leading edge technology for new product development," said
Kevin Rakin, President and Chief Executive Officer of Genaissance
Pharmaceuticals. "We look forward to developing a strong relationship with our
colleagues at Millennium."

"As a leading biopharmaceutical company, Millennium is committed to personalized
medicine, and we believe Genaissance`s technology will allow us to accelerate
our work in integrating DNA markers into clinical development and pharmaceutical
products," said Geoff Ginsburg, M.D., Ph.D., Vice President of Molecular
Medicine, Millennium Pharmaceuticals.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of personalized medicines. The Company
markets its technology and clinical development skills to the pharmaceutical
industry as a complete solution for improving the development, marketing and
prescribing of drugs. Genaissance currently has agreements with six of the top
pharmaceutical and biotechnology companies: AstraZeneca, Biogen, Johnson &
Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science
Park in New Haven, Connecticut.



Da kommt Freude auf, dieses Jahr wird es rosig aussehen.

[ZittrigeHand]

@ neoe
fragt sich nur ob dies auch für die aktionäre gilt

das teil war mal bei ca.23-25 $,ohne allianzen,ohne nix.
nun,ca.2 jahre später,deals mit den bigs(pfizer,biogen,etc....)eine technik die zu laufen scheint.....
und was ist !? der kurs ist im ar.......

[Neoe]

@zittrigehand:

Wer bei 23$-25$ eingestiegen ist, muß, wenn man annimmt, daß das Börsenklima langfristig so bleibt, damit rechnen, daß er wohl in den nächsten 5-10 Jahren keinen Gewinn mit dieser Aktie macht, sondern seinen Verlust begrenzt.

Ich persönlich bin bei umgerechnet 1,89 Euro eingestiegen und bin ja selbst so schon heillos im Minus.

Trotzdem muß man immer mit einem Hype rechnen, der für mich paradiesisch und für die Früheinsteiger immer noch lukrativ werden könnte.


Jetzt noch zwei interessante Artikel:

Der erste Artikel hebt die Beziehung von Pfizer und Genaissance hervor


Pfizer Hopes to Link Patients, Pills


By Mark D. Uehling
Bio-IT World

BOSTON (09/09/02)—It`s one of the medical world`s most neglected disorders. Pharmaceutical Company Bashing Syndrome (PCBS) afflicts growing numbers of congressmen, journalists, and investment analysts. PCBS is not life threatening, but it is highly contagious. Victims are chronically dissatisfied with drug prices and product pipelines in the pharmaceutical industry. But news from Boston after the Drug Discovery Technology World Congress in early August suggests that a cure for PCBS is on the horizon.

Unfortunately, the antidote is a pharmaceutical executive who stands more than 5 feet tall and will, as a result, be difficult to fit into a small plastic bottle. Patrice Milos manages pharmacogenomics and DNA sequencing at Pfizer Global Research and Development, a division of Pfizer Inc.

She doesn`t have a specific drug to boast about, and she won`t promise the moon. But Milos can articulate a sensible case for at least one scientific and IT challenge that large pharma companies, and only large pharma companies, can attempt. "We have unique opportunities as a large pharmaceutical company," Milos told the Boston audience. Milos explained that all of Pfizer`s clinical trials are now assessed for pharmacogenomic relevance. To wit: matching the genetic makeup of patients to specific medicines.

That could mean a medicine that didn`t quite pass muster in the past could be reintroduced and targeted only to those who will respond well to it, or who will not experience serious side effects.


Thinking big: Pfizer`s Patrice Milos sees potential in the challenges facing the big pharma.
"It wasn`t standard practice to be doing standard genotyping and using it in clinical trials," Milos said. "That`s what we set out to do." Milos said the project has been running for five years, which means it started well before the hoopla of the Human Genome Project began inflating expectations for most shareholders of drug and biotech stocks.

Pfizer`s program identifies selected patients in clinical trials and secures their consent to collect blood and genetic material, from which scientists extract DNA and RNA. The eventual goal of pharmacogenomics is to match a drug prescription not just to a patient of a certain age or sex but to a particular genetic and disease profile.

A first step down that path is cataloging the millions of subtle differences between individuals, or single nucleotide polymorphisms (SNPs). Pfizer is also compiling its own SNP data because, as with drugs, there could be money to be made from diagnostic tests used in conjunction with medicines.

"What we see is potentially widespread medical screening with SNP chips," Milos said. SNP screening tests could lead to medicines customized to fit the patient, she explained.

The promise of pharmacogenomics is that good responses and immunity to side effects could be predicted from Pfizer`s databases — repositories of information built with clinical data from the thousands of patients in Pfizer-sponsored medical studies. With a drug like the cholesterol-fighting Lipitor, Milos said, there may be 100,000 patients in a variety of ongoing clinical studies; Pfizer has hundreds of drugs at various stages of development. That`s a big pool of people to draw DNA from, though Milos won`t say how many people Pfizer has sampled.

To compile its pharmacogenomic database, Pfizer spent a year and a half building a system that would take patient data and "anonymize" it, stripping it of identifying personal information that would make it possible for patients to be tracked down later. That may sound like a legalistic frill, but sensitivity to privacy will help the company enroll patients. It could also inoculate the company against the bad publicity that might result after the unintended release of information about the genetic condition of an ordinary family.

As Milos outlined the complex interdisciplinary scientific and IT aspects of what Pfizer is exploring, it was clear that a smaller company would never have had access to so many patients, much less the money to do the project right. Likewise, Pfizer was smart enough to partner with a smaller, nimbler expert in pharmacogenomics: Genaissance Pharmaceuticals Inc. of New Haven, Conn.

But part of what makes the Pfizer pitch appealing is that it is understated and devoid of the often grandiose promises of small biotech companies. (Some researchers believe those promises are a cause of PCBS.)

"We think we have a strategic approach," Milos said. "I don`t think we`ve gotten it all right yet. But we`ve seen a lot of exciting developments over the past two years."





Nummer 2: Ein Lob für die von Genaissance geleistete Pionierarbeit.

CASE STUDY

Genaissance`s DecoGen Platform for Haplotyping


Successfully applying SNPs to clinical studies requires satisfying both biologists` and statisticians` IT needs



The DecoGen Informatics Platform contains three key components: the HAP Database, the DecoGen software suite, and an interface to SAS for performing association analysis. The DecoGen software suite comprises several applications that all use the same set of libraries and access the HAP Database.

Genaissance Pharmaceuticals Inc. realized early on that the cost of genotyping was turning pharmacogenomics into a numbers game, and so it became a leading proponent of and expert on haplotype mapping: the identification of heritable "sets" of linked SNPs.

"There is no other company that has done a better job on the scientific front," says DzGenes CEO Terrence Kungel. "They were tireless advocates of the haplotype concept."

Haplotype maps significantly reduce the number of SNPs that researchers need to survey. The company`s core resource is the HAP Database, which contains its haplotypes, as well as other genetic data, including appropriate parts of GenBank. The DecoGen software platform pulls everything together.

In designing the system, the first priority was to bring the right tools to the job, says Richard Judson, senior vice president of informatics at Genaissance. "We wanted to harness the power of SAS, but provide it in a way that was accessible for all of our scientists, even those who were less statistically sophisticated," he says. "DecoGen is kind of a preprocessor, which brings together the genetic data and clinical markers and hands that to SAS." Most other genetic analysis association software, he says, uses a more limited number of statistical techniques than are available through a bona-fide statistical package like the one SAS offers.

Researchers could get the same results just by writing SAS programs, but having it set up this way "makes it easier for us to ask a lot of genetic questions very quickly," Judson says.

The informatics must also evolve as rapidly as the science. Once Genaissance launched its STRENGTH trial of approximately 700 patients, it had to decide whether to incorporate the trial data into the main database. "We have this discussion regularly, and we always end up keeping it separate," Judson says. The company has separate clinical databases for each clinical program, mostly because "if real patient identifiers are still there, you have to limit access to that database."

The other reason is that statisticians tend to have a different approach to the analyses than most biologists and do a lot of preprocessing on clinical data. "Statisticians are constantly building small, specialized data sets to do particular analyses," Judson says. "If the clinical data was in the HAP Database they would lose the flexibility to create mini-data sets."

The idea of "loose coupling" is one of the philosophies driving Judson`s team. "Trying to build a single monolithic system to handle all of the data and analyses is too complex. Instead, we break the system into a small number of independent applications that talk to one another through well-defined interfaces," Judson says.

Building the system has been a learning process as well. "The first thing to realize is that trying to do everything yourself is a mistake," he says. "If there is something out there that you can use and integrate in, like SAS, that`s the best thing to do."

Analyzing that kind of data is one of the toughest jobs in genomics today. "We are analyzing a number of big data sets successfully," Judson says. "It does what we want it to do."

There is room for improvement, however. "The current architecture has some performance problems, and we are re-architecturing it to be more of a Web services system," he says. DecoGen is currently a fat client that runs on the user`s desktop, where it consumes a lot of resources. "If it is more server-based you could more easily have a big cluster behind the scenes," Judson says.

Customers have had the same performance issues, and next January Genaissance aims to release version 5.0, which should eliminate this problem. The first piece of that new system is RuleFinder, which currently runs on a cluster of 20 Pentium III boxes.

Genaissance also licenses the HAP Database and the DecoGen software platform. The product is usually installed in a client-server mode, with the HAP Database (which uses Oracle) residing on the server. It is accessed using the DecoGen software, which runs on a desktop client. The company is also considering licensing just the software. All of Genaissance`s systems run on standard hardware, including NT, other Windows operating systems, or UNIX

[Neoe]

Und ich kann euch auch schon Vorraussagen das diesen Monat zumindest eine weitere Nachricht kommt(siehe Zweiter Artikel aus Posting #59):

...There is room for improvement, however. "The current architecture has some performance problems, and we are re-architecturing it to be more of a Web services system," ...
....Customers have had the same performance issues, and next January Genaissance aims to release version 5.0, which should eliminate this problem.

[ZittrigeHand]

und wieder keine zahlen( $ ) dazu

klar,neoe,mir wärs verdammt nochmal lieb wenn das teil mal endlich anspringt.



......"As a leading biopharmaceutical company, Millennium is committed to personalized medicine, and we believe Genaissance`s technology will allow us to accelerate our work in integrating DNA markers into clinical development and pharmaceutical products," said Geoff Ginsburg, M.D., Ph.D., Vice President of Molecular Medicine, Millennium Pharmaceuticals


jep...wollen wir dies auch mal believen

[ZittrigeHand]

Genaissance Pharmaceuticals and Bayer Diagnostics Sign Pharmacogenomics Collaboration and License Agreement
Tuesday January 21, 7:02 am ET


NEW HAVEN, Conn., Jan. 21 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) announced today that it has entered into a collaboration with the Diagnostics Division of Bayer HealthCare LLC, a member of the Bayer Group (NYSE: BAY - News), to identify pharmacogenomic markers of drug safety and efficacy. Under the terms of the agreement, each party will contribute portions of intellectual property derived from its respective programs. Genaissance will receive funding to apply its HAP(TM) Technology to Bayer`s clinical samples. Bayer will receive exclusive rights to develop and market diagnostic tests based on the results of the collaboration. Genaissance will receive royalties and rights to perform these diagnostic tests in Genaissance`s CLIA-certified diagnostic laboratory. There are mutual royalty provisions for any pharmaceutical drugs derived from the cooperation.
ADVERTISEMENT


"We are pleased to enter into an agreement with Bayer, as a further step in commercializing our unique technology," said Kevin Rakin, President and CEO of Genaissance. "In working with Bayer, we have a partner that is well positioned to commercialize diagnostic tests stemming from this research collaboration. It is also a unique opportunity for Genaissance to utilize these markers for drug development efforts -- internally as well as with current and future pharmaceutical partners."

The collaboration will be based upon the pharmacogenomics research undertaken by Genaissance and by Bayer. Both parties contribute intellectual property to the collaboration. The goal of the collaboration is to use this pharmacogenomics intellectual property in combination with Genaissance`s HAP(TM) Technology to develop diagnostic tests that determine adverse drug response and efficacy response to existing drug classes as well as to newly developed drug products.

"Bayer Diagnostics is very pleased to be working with Genaissance, to utilize Genaissance`s haplotype technology for identification of diagnostic markers and therapeutic targets for individualized medicine," said Dr. William Wallen, Senior Vice President of Research at Bayer Diagnostics. "We view the collaboration as a unique opportunity to combine their pharmacogenomics expertise and our marker identification efforts to develop diagnostic tests that will ensure that therapeutic products deliver the maximum benefit to all patients."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. Genaissance markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with seven major pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Reports on Form 10-Q for the quarter ended June 30, 2002 and September 30, 2002 filed with the Securities and Exchange Commission on August 14, 2002 and November 14, 2002, respectively. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

Contact:

Kevin Rakin Rhonda Chiger (investors)
President & Chief Executive Officer Rx Communications
Genaissance Pharmaceuticals, Inc. 917.322.2569
203.786.3404 [e-mail]
[e-mail]




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.

[Neoe]

Wie nett, scheint als hätten wir nach der Kooperation mit Biogen, nun das zweite Unternehmen, daß die HAP-Technologie
direkt Medikamentbezogen einsetzt.
So wie es aussieht, könnte die Bayer-Kooperation alleine ausreichen, um GNSC über den Berg zu helfen.
Wenn man die Chancen als realistisch ansieht, daß GNSC für jedes Bayer-Medikament, das überprüft wird, ein Diagnostik-Kit entwickeln kann, sehe ich rosarot.

[Neoe]

Der Newsflow hält an:

Genaissance Pharmaceuticals Enters into a License Agreement with BD Genaissance Adds to its Pharmacogenomics Service Offering


NEW HAVEN, Conn., Jan 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genaissance
Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has entered into a
non-exclusive license agreement with BD (Becton, Dickinson and Company); (NYSE:
BDX) to add a component to its service offering. Genaissance will acquire a
license to BD`s proprietary BDProbeTec(TM) ET platform and Strand Displacement
Amplification (SDA) Technology for use in Genaissance`s CLIA compliant
diagnostic laboratory. BD will provide equipment, certain reagents and training
on the development of tests.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001024/NYTU035LOGO )

"We are delighted to enter into this agreement with BD, which enables us to
develop and offer new tests in our diagnostic laboratory," said Kevin Rakin,
President and Chief Executive Officer of Genaissance Pharmaceuticals. "We will
now be better positioned to serve our pharmaceutical partners in our
pharmacogenomic collaborations with validation studies and diagnostic tests to
support the marketing of drugs."

BDProbeTec(TM) ET is a platform developed by BD Diagnostic Systems, Sparks, MD,
that uses BD`s real-time amplification technology, SDA. BDProbeTec(TM) ET is
sold worldwide for molecular infectious disease testing.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of personalized medicines. The Company
markets its technology and clinical development skills to the pharmaceutical
industry as a complete solution for improving the development, marketing and
prescribing of drugs. Genaissance has agreements with eight major
pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, BD,
Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is
located in Science Park in New Haven, Connecticut.

[tui66]

Widerstand bei 1,4 USD scheint gebrochen.
Schlusstand auf Tageshoch 1,53 USD.

[tui66]

Aktie sieht prima aus , akt. USD 1,65!
Hat den keiner eine Meinung? Ich bin sehr positiv.

[Neoe]

tui66:

Natürlich hat hier einer eine Meinung. Aber meine kennst du ja schon.
Wir haben auf Tageshoch geschlossen 1,74$ und dürfen uns wohl auf weitere News freuen. Wir sollten auch nicht vergessen, daß GNSC sein Jahresziel eigentlich schon jetzt erreicht hat. Man strebt pro Jahr 2 (bis 3) Kooperationen an, um den Businessplan zu erfüllen. Dies wurde bereits im ersten Monat realisiert.
Und wir werden noch einiges mehr hören. GNSC ist über dem Berg und in einem Markt tätig, den viele vom Potenzial her noch nicht einmal ansatzweise einschätzen können.

Und das WO-Board hat es bisher gnadenlos verpennt!!!!

[ZittrigeHand]

und in einigen tagen kommen zahlen

bin mal gespannt



aber....schöner chart,sieht gesund aus(noch )

[ZittrigeHand]

Press Release Source: Genaissance Pharmaceuticals, Inc.


Genaissance Pharmaceuticals Reports Fourth Quarter And Full Year Results for 2002
Wednesday February 12, 7:01 am ET
- Record Fourth Quarter Revenues Underpinned by Solid Advances In Commercialization -


NEW HAVEN, Conn., Feb. 12 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today reported its financial results for the fourth quarter and year ended December 31, 2002.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001024/NYTU035LOGO )
For the quarter ended December 31, 2002, revenue was $2.6 million compared to $2.2 million for the fourth quarter of 2001. Operating expenses for the quarter decreased 59% to $6.1 million, of which $4.3 million was attributable to research and development. This compares to operating expenses of $15.0 million and research and development expenses of $12.0 million in the fourth quarter of 2001. Genaissance reported a net loss for the quarter ended December 31, 2002 of $5.6 million, or $0.24 per share, compared to a net loss of $11.4 million, or $0.50 per share, for the fourth quarter of 2001. In the quarter ended December 31, 2002, the Company recognized, as an expense, $1.8 million of remaining interest calculated in accordance with the agreements that Genaissance has with its two largest lease creditors. This interest expense was recorded as a result of their claims of default, which were previously disclosed by the Company. Excluding this charge, the net loss and loss per share for the fourth quarter of 2002 were $3.8 million and $0.17 per share, respectively.

Revenue for the year ended December 31, 2002 increased 52% to $8.1 million from $5.3 million for the same period of 2001. Operating expenses for the year 2002 totaled $38.7 million. Exclusive of the $6.0 million impairment charge in the second quarter, operating expenses in 2002 decreased 44% to $32.7 million, with $23.8 million attributable to research and development. This compares to operating expenses of $58.3 million and research and development expenses of $46.0 million for the year ended December 31, 2001. Genaissance reported a net loss for the year ended December 31, 2002 of $33.3 million, or $1.46 per share, compared to a net loss of $47.6 million, or $2.09 per share, for the year ended December 31, 2001. The decrease in research and development expenses is primarily due to completing the majority of the STRENGTH clinical trials in 2001 and reduced spending on reagents, payroll and other general expenditures, primarily resulting from the Company`s cost savings and restructuring program announced in August 2002.

As of December 31, 2002, Genaissance had cash, cash equivalents and marketable securities totaling $34.2 million.

"2002 was both challenging and productive for Genaissance. We are now a leaner, yet stronger organization, in tune with the needs of the pharmaceutical industry and squarely focused on commercialization," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Our revised business plan, launched in the second half of the year, has yielded gratifying results with the recent signing of four new collaborations, solidifying our leadership position in drug response pharmacogenomics. We are especially pleased with the substantial reduction in our operating cash burn in the fourth quarter and are entering 2003 with our business clearly on track for near term revenue growth and for building a long term strategic role in the industry."

Recent highlights include:

Existing Collaborations:

* Genaissance achieved a milestone with Johnson & Johnson Pharmaceutical
Research & Development (J&JPRD), the Company`s first HAP(TM)
Technology partner, which demonstrates the success of Genaissance`s
technology in identifying meaningful associations between genetic
variation and clinical observations. Genaissance continues to work
with J&JPRD on integrating the Company`s pharmacogenomics technology
into J&JPRD`s product development efforts.

* Genaissance and Pfizer extended their agreement through August 2004 to
allow Pfizer to gain non-exclusive access to selected portions of the
Company`s HAP(TM) Database.

Business Development:

* Genaissance announced four new agreements during the past few months,
including a drug-specific collaboration with Pharmacia. Under the
terms of the agreement, Pharmacia is licensing components of
Genaissance`s DecoGen(R) Informatics System for use in their drug
development process and Genaissance is applying its HAP(TM)
Technology to clinical trial samples from Pharmacia.

* Genaissance signed a multi-year HAP(TM) Technology Partnership
agreement with Millennium Pharmaceuticals. Millennium
non-exclusively licensed Genaissance`s technology for use in internal
and partnered drug discovery and development programs. Under the
terms of the agreement, Millennium will pay Genaissance license fees
and Genaissance will have certain rights to support Millennium`s DNA
biomarker and pharmacogenomics efforts.

* Genaissance recently announced its first commercial agreement
resulting from the Company`s pharmacogenomics research. Genaissance,
in partnership with the Diagnostics Division of Bayer HealthCare LLC,
a member of the Bayer Group, will develop diagnostic tests that
determine adverse drug response and efficacy response to existing
drug classes as well as to newly developed drug products.
Genaissance will receive royalties and the rights to perform these
diagnostic tests in the Company`s CLIA-licensed genotyping
laboratory. This partnership could generate the first products to be
developed using pharmacogenomics, with the potential for an initial
diagnostic product to be available in 2005. Genaissance also intends
to pursue additional collaborations around the Company`s
pharmacogenomics research data.

* Genaissance entered into a license agreement with BD (Becton,
Dickinson and Company). Under the terms of the agreement, BD will
provide certain technologies, equipment, reagents and training on the
development of diagnostic tests in exchange for certain royalty
payments. This agreement provides Genaissance with the platform to
offer its pharmaceutical partners validation studies and diagnostic
tests, conducted in the Company`s CLIA-licensed genotyping
laboratory, to support the marketing of drugs.


"We are pleased by the positive momentum that has occurred over the past few months. In addition, another encouraging development for the growth of our business is the FDA`s recent announcement that the agency will be providing guidance on the use of pharmacogenomics in drug development," said Mr. Rakin. "Our focus remains on completing deals and thereby continuing to reduce our burn rate so as to ensure a fiscally and strategically sound company for the long term."

For the fiscal year 2003, Genaissance issues the following guidance:

* Revenues to be between $10 and $12 million;

* Operating expenses to be between $25 and $26 million, including
approximately $7.5 million of non-cash depreciation expense; and

* Net loss to be between $14 and $16 million.


As previously announced, Genaissance will host a conference call to discuss these financial results today at 10:00 am, Eastern Standard Time. To participate in this call, dial 719-457-2657, confirmation code 661427, shortly before 10:00 am. A replay of the call will be available from 1:00 pm, Eastern Standard Time through midnight Tuesday, February 18, 2003. The replay number is 719-457-0820, confirmation code 661427.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with eight major pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, BD (Becton, Dickinson and Company), Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2002, June 30, 2002 and September 30, 2002 as filed with the Securities and Exchange Commission on May 14, 2002, August 14, 2002 and November 14, 2002, respectively. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

GENAISSANCE PHARMACEUTICALS, INC.

Statements of Operations
(Unaudited)
(In thousands, except per share data)


Three Months Ended Year Ended
December 31, December 31,
2002 2001 2002 2001

License and service
revenue $2,573 $2,196 $8,111 $5,345

Operating Expenses:
Research and
development 4,280 11,990 23,837 46,036
General and
administrative 1,960 2,885 8,890 11,786
Stock based
compensation (95) 117 12 498
Impairment of fixed
assets -- -- 6,000 --

Total operating
expenses 6,145 14,992 38,739 58,320

Loss from operations (3,572) (12,796) (30,628) (52,975)

Interest (expense),
income net (2,009) (84) (2,660) 1,319
Income tax (expense)/
benefit (8) 1,500 (35) 4,074

Net loss attributable
to common
stockholders $(5,589) $(11,380) (33,323) (47,582)

Net loss per common share,
basic and diluted $(0.24) $(0.50) (1.46) (2.09)

Weighted average shares
used in computing Net
loss per common share 22,827 22,774 22,809 22,753

Balance Sheet Data
(in thousands)
(unaudited)

Dec. 31, Dec. 31,
2002 2001

Cash, cash equivalents and marketable
securities $34,150 $59,673
Working capital 16,131 47,775
Total assets 50,722 92,277
Capital leases and current portion
long term debt 11,814 17,265
Long term debt 4,502 4,929
Stockholders` equity 25,625 58,979




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.

[ZittrigeHand]

heute ist ein 100.000 er trade übern tisch gegangen

[Neoe]

Genaissance Promotes Dr. Carol Reed to Vice President, Medical Affairs
Friday February 14, 9:46 am ET


NEW HAVEN, Conn., Feb. 14 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that Carol Reed, M.D., is being promoted to Vice President, Medical Affairs. Dr. Reed, who previously held the position of Executive Director, Medical Affairs, is responsible for the Company`s Drug-Specific Partnership Collaborations and internal clinical programs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001024/NYTU035LOGO )
"Dr. Reed has been instrumental in maximizing the medical utility of the associations we`ve discovered in our STENGTH trials and in our partnered programs," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "She will now also be responsible for configuring these associations into the development of products for commercial use as well as be the key alliance manager for collaborations focused on product development."

Dr. Reed, 49, joined Genaissance from Bayer Pharmaceuticals, Inc., where she was an Associate Medical Director in Pulmonary Medical Research. In that role, Dr. Reed was responsible for medical monitoring, protocol design and patient safety. Previously, she was the Associate Director, Section of Pulmonary and Critical Care Medicine at the Hospital of St. Raphael and directed its Medical Intensive Care Unit. Dr. Reed received a M.S. in Molecular Biology from the University of Illinois and a M.D. from the Rush Medical College in Chicago.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with eight major pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, BD (Becton, Dickinson and Company), Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

[ZittrigeHand]

Press Release Source: Genaissance Pharmaceuticals, Inc.


Genaissance Pharmaceuticals Announces Additions to the Company`s Patent Estate
Wednesday February 26, 7:01 am ET
- Allowed Patent Claims Directed to Clinical Associations for Predicting Drug Response -


NEW HAVEN, Conn., Feb. 26 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) announced today that it received two key notices from the U.S. Patent and Trademark Office. The first is a notice of allowance for the Company`s patent application on clinical associations that predict an individual`s bronchodilating response to the drug albuterol, used in the treatment of asthma. The associations, which were previously described in the September 2000 edition of the scientific publication Proceedings of the National Academy of Sciences, were discovered using Genaissance`s HAP(TM) Technology. The Company also announced that it was granted a U.S. patent (Number 6,521,747 B2) for haplotypes of the gene encoding angiotensin receptor 1, which is a target for drugs used to treat hypertension.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001024/NYTU035LOGO )
"These recent patent notices validate Genaissance`s intellectual property strategy for linking gene variation to clinical response and add an important element to our commercialization plan," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Along with our recent partnership announcements, we believe our growing patent estate solidifies our corporate strategy of developing a new generation of diagnostic and therapeutic products that include haplotype markers."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with eight major pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, BD (Becton, Dickinson and Company), Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2002, June 30, 2002 and September 30, 2002 as filed with the Securities and Exchange Commission on May 14, 2002, August 14, 2002 and November 14, 2002, respectively. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.

[tui66]

sieht bis jetzt prima aus - 1,47 Dollar.
Umsätze sind jedoch niedrig. Denke es wird
charttechnisch die nächsten Tage nach oben gehen.
kurzfr. Abwärtstrend dürfte wohl gebrochen werden.

[Neoe]

Nachgereicht mal noch ein paar News:



Genaissance Pharmaceuticals Signs Agreement with Wayne State University to Support the NIH`s Perinatology Research Branch
Tuesday March 25, 7:00 am ET


NEW HAVEN, Conn., March 25 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has signed an agreement with Wayne State University (WSU) to support WSU`s research contract with the National Institute of Child Health and Human Development`s Perinatology Research Branch (PRB), which is located at the WSU School of Medicine in Detroit, Michigan. Under the agreement, WSU will gain access to specific HAP (TM) Markers and obtain a limited license to use the Company`s DecoGen (R) Informatics System. Genaissance will develop assays for the selected HAP (TM) Markers and provide high-throughput genotyping on clinical samples provided by WSU and the PRB. Genaissance will receive a license fee and other payments from WSU.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001024/NYTU035LOGO )
"We are delighted to enter into an agreement with WSU, which is working with the PRB to address important healthcare issues of adverse pregnancy outcomes," said Gerald F. Vovis, Ph.D., Executive Vice President and Chief Technology Officer of Genaissance Pharmaceuticals. "This is our first major agreement in the public sector and reinforces the utility of our HAP (TM) Technology for helping to detect associations between clinical outcomes and genetic variation."

About Genaissance:

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with eight major pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, BD (Becton, Dickinson and Company), Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

About Wayne State University:

With more than 1,000 medical students, WSU is among the nation`s largest medical schools. Together with its clinical partner, the Detroit Medical Center, the school is a leader in patient care and medical research in a number of areas, including cancer, genetics, the neurosciences and women`s and children`s health.

This press release contains forward-looking statements, including statements about the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2002, June 30, 2002 and September 30, 2002 as filed with the Securities and Exchange Commission on May 14, 2002, August 14, 2002 and November 14, 2002, respectively. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

...........................................................


Genaissance Pharmaceuticals Enters into Agreement To Acquire Assets of DNA Sciences
Tuesday April 1, 6:02 am ET
Proposed Acquisition Would Add Additional Pharmacogenomics Expertise


NEW HAVEN, Conn., and FREMONT, Calif., April 1 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) announced today that it has entered into an agreement to acquire substantially all of the assets of DNA Sciences, Inc. for approximately $1.3 million in cash and common stock. DNA Sciences today also announced that it has voluntarily filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of California. Concurrently, DNA Sciences will seek bankruptcy court approval for a pre-negotiated asset purchase agreement by Genaissance. Under the terms of the agreement, Genaissance would acquire substantially all of DNA Sciences` assets, subject to bankruptcy court proceedings and approval and customary closing conditions, which the two parties expect to occur within 60 days.
ADVERTISEMENT


"This proposed transaction would further our goal of building a comprehensive business in drug response pharmacogenomics while maintaining our internal financial benchmarks," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "The post-acquisition Genaissance would be a true one-stop shop for the healthcare industry to apply pharmacogenomics to drug development. After completing the integration, we would expect to have greater revenue, a larger client base, additional genotyping services, a broadened intellectual property estate and an enhanced ability to develop proprietary products. Overall, the DNA Sciences acquisition complements our commercial, financial and clinical goals. We believe that this acquisition would be cash flow positive in 2004 and, thus, would contribute to our goal of reaching financial breakeven in 2005."

"By joining forces with Genaissance, our employees, customers and technology partners would benefit from a company that has significant market share in the area of pharmacogenomics," said Steven Lehrer, President and Chief Operating Officer of DNA Sciences. "Genaissance understands the full potential of DNA Sciences` products and technology. With our assets, Genaissance would have knowledge and expertise to greatly improve patient care through the use of pharmacogenomics."

About Genaissance Pharmaceuticals, Inc.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with eight major pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, BD (Becton, Dickinson and Company), Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

About DNA Sciences, Inc.

DNA Sciences, Inc. is a privately held applied genetics company focused on developing DNA diagnostics for critical medical and therapeutic decisions. The company utilizes DNA based tests in clinical trials to understand differential response to medication and diagnose diseases state. It has a combination of research and GLP/CLIA facilities and is involved in a broad range of genetics activities extending from discovery and development to genetic testing services. DNA Sciences is also a leading provider of pharmacogenetic services to the pharmaceutical industry. DNA Sciences is based in Fremont, California and was founded in May 1998. Visit the company`s website at www.dna.com.

[Neoe]

Zu empfehlen:

www.dna.com

Ihr werdet einige interessante Namen hier finden. Genaissance arbeitet jetzt indirekt mit Glaxo, Bristol-Myers, Merck KGaA, Amersham, usw. zusammen. DNA Sciences hat Verbindungen zu 18 der Top 25 Pharmaunternehmen.Das Board of Directors lässt auch einiges erahnen.

Besonders interessant finde ich die Zusammenarbeit mit Amersham, mal sehen wenn es da was zu hören gibt.

[tui66]

könnte charttechnisch die Trendwende sein. 38-Tage-Durchschnitt überwunden. Umsätze haben angezogen.
Hat das was mit der Zusammenarbeit mit der Wayne State University zu tun? Info ist doch schon ein paar Tage alt!

egal

[ZittrigeHand]

tui
GNSC war mir schon immer ein rätsel

[ZittrigeHand]

noch jemand dabei ?

heute + 13/17%
hab ich was verpasst

das teil läuft nur wenn NAZ im minus iss

[Neoe]

Am 13.Mai ist der Conference Call zum 1. Quartal. Mal sehen in welche Umsatzbereiche GNSC mit den neuen Kooperationen vorgestoßen ist, außerdem sollen auch einige Infos zu DNA Sciences kommen. Vielleicht machen sie Angaben in welcher Größenordnung DNA S. Umsätze beisteuern wird.

[ZittrigeHand]

Genaissance Pharmaceuticals` Acquisition of Substantially All of the Assets of DNA Sciences Is Approved
Monday May 12, 4:15 pm ET
- Combination Will Create a Leading Pharmacogenomics-Based Drug Response Company -


NEW HAVEN, Conn., May 12 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that a United States bankruptcy judge has approved the acquisition by Genaissance of substantially all of the assets of DNA Sciences, Inc. for $1.35 million in cash. Genaissance and DNA Sciences are working towards a prompt closing of a pre-negotiated asset purchase agreement. In addition, Genaissance expects to enter into a modification of a license agreement, relating to the purchased assets, that will result in a net cost of the purchase, including all legal and advisory costs, of approximately $1 million.
"This acquisition will enhance our HAP(TM) Technology and solidify us as the partner of choice for the development of pharmacogenomics-based drug response products," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We believe that the acquisition will have an immediate impact on our revenues, with pro forma revenues for 2003 of $12.5 to $14.5 million. Through June 2004, we expect the earnings per share to be diluted by $0.01 per quarter, becoming accretive in the third quarter of 2004."

Among the assets that Genaissance is acquiring from DNA Sciences are:

* DNA Sciences` Morrisville, North Carolina GLP compliant and CLIA
licensed facility, which is a leader in providing clinical trial
genotyping services and diagnostic tests to the pharmaceutical
industry;

* a patent estate, including exclusive licenses from The University of
Utah and Yale University to patents for diagnosing Long QT Syndrome
(LQT), a potential life threatening side-effect of various drugs; and

* a commercially available thiopurine S-methyltransferase (TPMT)
diagnostic test for identifying adverse effects caused by the
thiopurine class of drugs, from which DNA Sciences is receiving
royalties from its sub-licensees.


The acquisition will be consistent with Genaissance`s business strategy of generating current revenues from pharmacogenomics-based products and of establishing contractual rights for royalties from the sales of drugs and diagnostic tests. The benefits include:

* Strategically, Genaissance is focused on applying genetic variability
to predicting drug response. By combining DNA Sciences` GLP and CLIA
facility for genotyping with its HAP(TM) Technology and high-throughput
research genotyping capabilities, Genaissance will provide a complete
range of offerings for the application of DNA tests to the clinical
development and marketing of drugs. Additionally, Genaissance will
seek to broaden its relationships with the numerous pharmaceutical and
biotechnology clients that have existing agreements with DNA Sciences
by offering them access to Genaissance`s HAP(TM) Technology platform as
well as offering Genaissance`s existing customers access to its newly
acquired GLP and CLIA facility for their genotyping needs.

* Scientifically, Genaissance is focused on using proprietary DNA-based
technology to improve the clinical development and marketing of drugs.
Similarly, DNA Sciences provides DNA-based tests for use in clinical
trials to understand differential response to medication and to
diagnose disease states. In addition, DNA Sciences has a patent estate
in cardiac arrhythmia genetics, for which it has exclusively licensed
patents for diagnosing LQT. Genaissance will seek to commercialize
this intellectual property with a partner.

* Commercially, Genaissance has a goal of reaching financial break-even
in 2005. DNA Sciences has current annualized revenues of approximately
$2.5 million. Genaissance believes that these revenues will grow in
excess of 25% annually and result in accretion to earnings in the third
quarter of 2004.


"We already have integration teams in place and are confident that the transition will be seamless to DNA Sciences` customers," added Kevin Rakin. "We are excited about bringing together these two companies and believe that we will create a true powerhouse in the area of pharmacogenomics-based products and services. It is a challenging time for the industry and we believe that this acquisition will add significant value to Genaissance at minimal cost and no strain to our balance sheet. We are eager to begin moving the combined company forward and enhancing our commercial opportunities."

About LQT

LQT is caused by structural abnormalities in the potassium and sodium channels of the heart, which predispose affected persons to an abnormal heart rhythm (dysrrhythmia). LQT can be inherited or acquired. Seven genes, which encode ion transport channels, have been identified as causal for inherited LQT, with each of the genes having multiple causative polymorphisms. Acquired LQT is often due to the administration of a medication. More than 50 approved prescription medications, in virtually every therapeutic class, are thought to prolong the QT-interval. Drug-induced LQT has led to the withdrawal from the market of such well-known drugs as the heartburn agent Propulsid and the antihistamine Seldane.

About TPMT

The thiopurine class of drugs is commonly used as anti-cancer therapeutic agents. For patients taking these drugs, the ability to produce TPMT enzyme activity is essential for normal metabolism of these medications. The level of TPMT activity impacts both the efficacy and toxicity of the therapies. Genotyping has become a reliable and rapid method to identify patients who are TPMT deficient, thereby, allowing the physician to tailor drug therapy for the best possible outcome.

Legg Mason Wood Walker, Inc. acted as a special bankruptcy advisor to Genaissance in this transaction.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

This press release contains forward-looking statements, including statements about the expected growth and development of Genaissance`s business, expected financial performance, the entering into by Genaissance of a license agreement with respect to certain intellectual property rights, the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003, as amended. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.

[ZittrigeHand]

Genaissance Pharmaceuticals Reports First Quarter Results
Tuesday May 13, 7:15 am ET
- Quarter Highlighted by Four Deals and the Acquisition of DNA Sciences -


NEW HAVEN, Conn., May 13 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today reported its financial results for the first quarter ended March 31, 2003.
For the three months ended March 31, 2003, revenues grew 16% to $2.1 million, compared to $1.9 million for the first quarter of 2002. Operating expenses for the quarter decreased significantly, 37%, to $6.8 million, of which $4.7 million was attributable to research and development. These results compare to operating expenses of $10.7 million, of which $8.3 million was attributable to research and development, for the first quarter of 2002. The decrease in overall operating expenses was primarily due to the 43% reduction in research and development expenses. Genaissance reported a net loss of $4.7 million, or $0.21 per share, for the first quarter of 2003, compared to a net loss of $9.1 million, or $0.40 per share, for the first quarter of 2002.

As of March 31, 2003, the Company had cash, cash equivalents and marketable securities totaling $30 million, consistent with Genaissance`s previously announced cash projections.

Highlights of the quarter include:

* Genaissance signed agreements with Millennium Pharmaceuticals, Inc.,
the Diagnostics Division of Bayer HealthCare LLC and BD (Becton,
Dickinson and Company). Millennium, like Genaissance, has a vision of
personalized medicine and will include Genaissance`s HAP(TM) Technology
in its drug development programs. Genaissance`s agreement with Bayer
HealthCare commercializes the associations generated from the Company`s
STRENGTH trials with the goal of developing diagnostic tests that
determine adverse drug response and efficacy response. The BD
agreement provides Genaissance with access to a diagnostic platform
that can be used to validate associations and commercialize diagnostic
tests. Genaissance continues to align itself with leaders in the
healthcare industry and has expanded the commercialization of its
HAP(TM) Technology into diagnostic tests.

* Genaissance entered into an agreement with Wayne State University (WSU)
to support WSU`s research contract with the National Institute of Child
Health and Human Development`s Perinatology Research branch, which is
located at WSU`s School of Medicine. This agreement is Genaissance`s
first in the public sector. WSU gained access to specific HAP(TM)
Markers and obtained a limited license to use the Company`s DecoGen(R)
Informatics System. Genaissance is developing assays for the selected
HAP(TM) Markers and providing high-throughput genotyping on clinical
samples provided by WSU. Genaissance will receive a license fee and
other payments from WSU. This agreement not only represents a new
market for Genaissance but it also takes advantage of the Company`s
genotyping expertise and infrastructure.

* The U.S. Patent and Trademark Office issued two key notices to
Genaissance. The first was a notice of allowance for the Company`s
patent application on clinical associations that predict an
individual`s bronchodilating response to the drug albuterol, which is
used in the treatment of asthma. Genaissance was also granted a U.S.
patent for haplotypes for the gene encoding angiotensin receptor 1,
which is a target for drugs used to treat hypertension. These two
notices further solidify Genaissance`s prominence in the area of
pharmacogenomics and enhance the Company`s commercialization efforts.


As announced yesterday, Genaissance has received court approval and expects to close shortly on acquiring substantially all of the assets of DNA Sciences, Inc. for $1.35 million. In addition, Genaissance expects to enter into a modification of a license agreement, relating to the purchased assets, that will result in a net cost of the purchase, including all legal and advisory costs, of approximately $1 million.

"We believe that our ability to continue to grow our revenue base and enter new markets, while decreasing our burn rate, is a testament to the value of our technology and our commitment to executing our business plan," said Mr. Rakin, President and Chief Executive Officer. "During the next several months, we will be integrating DNA Sciences into the Company. We believe that this acquisition will enhance our core capabilities and enable us to broaden our appeal to potential pharmaceutical and biotechnology partners. We are now giving guidance that our pro forma revenues for calendar 2003 will be between $12.5 and $14.5 million. Through June 2004, we expect that the acquisition of DNA Sciences will dilute our earnings each quarter by an additional $0.01 per share, with the acquisition becoming accretive in the third quarter of 2004."

Genaissance will host a conference call and web cast to discuss events disclosed in this press release. The previously announced call is scheduled for today at 11:00 a.m., Eastern Time. To participate in this call, dial 719- 457-2620, confirmation code 117471, shortly before 11:00 a.m. A replay of the call will be available from 2:00 p.m., Eastern Time through midnight Monday, May 19, 2003. The replay number is 719-457-0820, confirmation code 117471. The web cast can be accessed at www.genaissance.com.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com

This press release contains forward-looking statements, including statements about the expected growth and development of Genaissance`s business, expected financial performance, the entering into a modification of a license agreement with a third party with respect to the acquisition of DNA Sciences, the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003, as amended. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

GENAISSANCE PHARMACEUTICALS, INC.

Statements of Operations
(Unaudited)
(In thousands, except per share data)

March 31,
2003 2002


License and service revenue $2,139 $1,851

Operating Expenses:
Research and development 4,739 8,282
General and administrative 2,059 2,457


Total operating expenses 6,798 10,739


Loss from operations (4,659) (8,888)


Interest income 134 354
Interest expense (201) (526)

Net loss attributable to common stockholders $(4,726) $(9,060)


Net loss per common share, basic and diluted $(0.21) $(0.40)


Weighted average shares used in computing
Net loss per common share 22,865 22,786


Balance Sheet Data
(in thousands)
(unaudited)

March 31, Dec. 31,
2003 2002

Cash, cash equivalents and marketable securities $ 30,014 $ 34,150
Working capital 13,206 16,361
Total assets 44,884 50,722
Capital Leases and current portion long term debt 9,967 11,584
Long Term debt 4,432 4,501
Stockholders` equity 21,466 25,855




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.

man beachte die 0,01 für 2004

[ZittrigeHand]

Genaissance Pharmaceuticals Expands Licensing Agreement With Prometheus Laboratories for TPMT Diagnostic Test
Friday May 16, 7:15 am ET
- Collaboration Focused on Developing Additional Pharmacogenomics-Based Tests -


NEW HAVEN, Conn. and SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) and Prometheus Laboratories Inc. today announced that they have expanded their agreement, under which Prometheus has licensed rights from Genaissance to a thiopurine S-methyltransferase (TPMT) diagnostic test, to include a broader field of use. The TPMT test provides a genetic assessment of a patient`s ability to metabolize the thiopurine class of drugs.
ADVERTISEMENT
AMERITRADE SPECIAL OFFER

· 30 commission-free trades
Start trading on us
· Command center screen
Get this FREE service
· Our 10-Second Guarantee
(restrictions apply)

Start getting your share with us
Open your account now





The intellectual property surrounding the TPMT technology and the licensing agreement with Prometheus were part of the assets that Genaissance acquired yesterday upon the closing of its purchase of substantially all of the assets of DNA Sciences, Inc. Genaissance received an upfront license fee from Prometheus for the expansion of the license agreement and will receive royalties based on net sales. In addition, Genaissance announced that the two companies plan to collaborate in identifying HAP(TM) Markers that are predictive of patient response to therapies in Prometheus` areas of interest. Prometheus is focused on disorders associated with the gastrointestinal tract as well as autoimmune and inflammatory diseases.

"We are pleased to have gained additional value from the assets that were acquired from DNA Sciences," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Prometheus, like Genaissance, is striving to integrate therapeutics and diagnostics in order to improve patient outcomes. We look forward to working with Prometheus on identifying HAP(TM) Markers that are predictive of patient response and subsequently working to develop diagnostic tests for commercialization by Prometheus."

"We now have the exclusive rights to a broader field of use for TPMT genetics," said James A. Schoeneck, President and Chief Executive Officer of Prometheus Laboratories. "Our PRO-PredictRx® TPMT test provides a reliable genetic assessment that the physician can use to help identify patients at risk for adverse events prior to initiating thiopurine therapy. Our goal in our collaboration with Genaissance is to add innovative diagnostics to our current pipeline of products as Prometheus continues to deliver on the promise of personalized medicine."

About TPMT

The thiopurine class of drugs is commonly used to treat autoimmune and inflammatory diseases. For patients taking these drugs, the ability to produce the TPMT enzyme is essential for metabolism of these medications. The level of TPMT activity impacts both the efficacy and toxicity of the therapeutics. Genotyping has become a reliable and rapid method to identify patients who are TPMT deficient, thereby, helping the physician tailor drug therapy for the best possible outcome.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. Prometheus focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Prometheus` strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating these therapeutic, diagnostic and treatment monitoring services, Prometheus addresses the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus` corporate offices are located in San Diego, California. Additional information about Prometheus Laboratories can be found at www.prometheuslabs.com.

About Genaissance

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

This press release contains forward-looking statements, including statements about the expected growth and development of Genaissance`s and Prometheus` respective businesses, potential benefits to be derived from the Prometheus licensing agreement, the ability of Genaissance and Prometheus to apply their technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the adoption of technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of Genaissance`s and Prometheus` intellectual property rights and those risks identified in Genaissance`s Quarterly Report on Form 10-Q for the quarter ended March 31, 2003 as filed with the Securities and Exchange Commission on May 15, 2003, and in other filings made from time to time with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Genaissance and Prometheus as of the date of this release. Genaissance and Prometheus disclaim any obligation to update any forward-looking statement.




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.



gute zuwächse

[ZittrigeHand]

sieht stabil aus

[ZittrigeHand]

430 k shares bis jetzt gehandelt

[ZittrigeHand]

`ne knappe halbe mill.shares heute,dazu noch + 17%
wird zeit das das baby mal über die 2 $ marke klettert


bin ich der einzige GNSC shareholder in germany

[IchWeissDassIchNichtsWeiss]

hier ist auch noch ein versprengter aktionär, bin schon seit 2 Jahren (damals noch zu über 12 $ dabei) und habe die Kohle ( ist ja jetzt nicht mehr viel) schon abgeschrieben. Vor 2 Wochen habe ich aber dann nachgekauft.

[Neoe]

ZittrigeHand@:

Na ich bin ja auch noch da. Warte mal ab. Demnächst kommen die Guidelines der FDA. Bisher schweben die Proteomics-Firmen noch im "rechtsfreien" Raum, doch jetzt kommt der Paradigmenwechsel auf uns zu, ich würde sagen das wichtigste Ereignis für GNSC in 2003.

[ZittrigeHand]

grade über 2 $ gehüpft !

goooooo baaaaaaby gooooooooooooooooooooooooo

[Neoe]

Hier braut sich was zusammen. Die Gründe sind vielfältig:

Gutes Marktumfeld, die kommenden FDA-Guidelines und demnächst Produktneueinführungen.
Unter den diversen Tests, die kurz vor der Vermarktung stehen ist vor allem auch das DNA Sciences Patent zur Diagnose des LongQT-Syndroms überaus interessant. Ich gehe davon aus, daß man den alten Partner beibehalten wird (GlaxoSmithKline)....Müsste bald mal eine Meldung diesbezüglich kommen.

[Neoe]

Genaissance Pharmaceuticals Appoints Skip Klein to Board of Directors
Tuesday July 8, 7:30 am ET


NEW HAVEN, Conn., July 8 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced the appointment of Skip Klein to its Board of Directors, increasing the number of directors to seven.
ADVERTISEMENT


"We are delighted to welcome Skip to our Board," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "As a veteran investor in the biotech industry for the past 15 years, Skip`s deep understanding of the sector, coupled with his unique shareholder value creation perspective, public company board experience, and strong financial capabilities, should make him an invaluable member of our Board as we continue to pursue our development and growth goals over the coming years."

Mr. Klein, 42, is currently Managing Director of Gauss Capital Advisors, LLC, an investment due diligence and advisory firm focusing on the identification of promising health technology investments. Prior to founding Gauss Capital in 1998, Mr. Klein spent a decade at T. Rowe Price Associates in various health care investment roles, including the last as founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Under his direction, the Fund grew from $2 million in assets in 1995 to $290 million in assets in 1998, and was named the top performing health care fund in 1996 as measured by Lipper Analytical Services. Since leaving T. Rowe Price, Mr. Klein has served as health care investment analyst at The Kaufmann Fund, and Vice President of Strategy of Medical Manager Corporation until its merger with WebMD. More recently, Mr. Klein served as Venture Partner at MPM Capital, one of the largest venture capital and public equity investors devoted exclusively to health care. Mr. Klein also serves on the Board of Directors of Guilford Pharmaceuticals and NPS Pharmaceuticals, where he is Chairman of the Audit Committee. He earned a B.A. degree from Yale University and an M.B.A. from Stanford Graduate School of Business. Mr. Klein is a Chartered Financial Analyst and Chartered Financial Consultant.

On his appointment to the Genaissance Board, Mr. Klein commented: "Having spent a great deal of time analyzing Medco Containment Services and the methods its management used to build shareholder value, I am struck by the potential for Genaissance to become a fourth generation pharmacy benefit manager (PBM) -- using pharmacogenomics to guide the intelligent, efficient use of pharmaceuticals by physicians, patients and payors. I am impressed by the ability of Kevin Rakin and the management team to begin to execute on their compelling vision. The recent successful acquisition of the assets of DNA Sciences, including promising work and intellectual property around long QT, demonstrates the ability of the team to identify and build value for shareholders at a challenging time for any company working on the promise of genomics."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

[ZittrigeHand]

Dow Jones Business News
Genaissance Pharmaceuticals` Ruano to Resign Aug. 31
Tuesday July 29, 11:52 am ET


NEW HAVEN, Conn. (Dow Jones)--Genaissance Pharmaceuticals Inc. said Chief Scientific Officer and co-founder Gualberto Ruano will resign Aug. 31.
A company spokesman wasn`t immediately available to comment on the resignation.

In a press release Tuesday, the pharmaceutical company said it named Richard S. Judson to the post.

Judson, 44 years old, was senior vice president, medical affairs and informatics, since August 2000.

Genaissance, which was founded in 1997, posted a 2002 loss of $33.3 million, or $1.46 a share, on revenue of $8.1 million.

The company`s shares traded recently at $1.48, down 2 cents, or 1.3%, on Nasdaq volume of 10,600 shares. Average daily volume is 99,076 shares.

Company Web site: http://www.genaissance.com

-Stephen Lee; Dow Jones Newswires; 201-938-5400



der kurs sieht auch scheisse aus,die firma fuckt mich ab

[Neoe]

Sind das gute oder wahnsinnig gute Zahlen:


Genaissance Pharmaceuticals Reports Second Quarter Results
Wednesday August 13, 7:30 am ET
- Record Quarterly Revenue and Integration of DNA Sciences Highlights Quarter -


NEW HAVEN, Conn., Aug. 13 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today reported its financial results for the second quarter and half-year ended June 30, 2003.
For the three months ended June 30, 2003, revenues grew 61% to $3.1 million, compared to $1.9 million for the same period last year. Operating expenses for the current quarter decreased to $7.1 million, of which $5.1 million was attributable to research and development. These results compare to operating expenses of $15.2 million, of which $6.6 million was attributable to research and development, for the three months ended June 30, 2002. The 2002 results include a non-cash charge, taken in the second quarter of 2002, of $6.0 million related to the write-down of certain fixed assets, which the Company determined were impaired under current accounting rules. Genaissance`s net loss for the three months ended June 30, 2003, narrowed to $3.8 million, or $0.17 per share, compared to a net loss of $13.5 million, or $0.59 per share, inclusive of the non-cash charge, for the three months ended June 30, 2002.

For the six months ended June 30, 2003, revenues grew 39% to $5.3 million, compared to $3.8 million for the same period last year. Operating expenses for the six months ended June 30, 2003, were $13.9 million, with $9.8 million attributable to research and development. These results compare to operating expenses of $25.9 million for the six months ended June 30, 2002, of which $14.9 million was attributable to research and development and $6.0 million related to the non-cash charge. The Company reported a net loss for the six months ended June 30, 2003, of $8.5 million or $0.37 per share, compared to a net loss of $22.5 million or $0.99 per share, inclusive of the non-cash charge, for the six months ended June 30, 2002.

As of June 30, 2003, the Company had cash, cash equivalents and marketable securities totaling $23.3 million.

"One year after we implemented our restructuring plan, I am pleased to report that the goals of the restructuring have been met," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Our base business is meeting the targets we set for increasing revenues and steadily reducing our burn rate. During this quarter, we achieved the largest quarterly revenues and the lowest net loss since going public. Our acquisition of DNA Sciences enhances our ability to build a profitable base business and solidifies our leadership position in drug response pharmacogenetics. With our restructuring goals behind us, we will continue to focus on increasing our revenue base, including evaluating acquisition candidates, with the added goal of developing a smart product development approach for our proprietary programs."

Highlights of the quarter include:

Acquisition of Substantially All of the Assets of DNA Sciences

* In May, immediately following the close of the acquisition, Genaissance
entered into a licensing agreement with Prometheus Laboratories under
which Genaissance licensed Prometheus additional rights to a thiopurine
S-methyltransferase (TPMT) diagnostic test, which Genaissance acquired
from DNA Sciences. The TPMT test provides a genetic assessment of a
patient`s ability to metabolize the thiopurine class of drugs, which
are commonly used to treat autoimmune and inflammatory diseases.
Genaissance received an upfront license fee of $675,000 from Prometheus
and receives royalties based on net sales. In addition, Genaissance
and Prometheus intend to collaborate in identifying HAPO Markers that
are predictive of a patient`s response to therapies in other areas of
interest to Prometheus.

* Genaissance completed the integration of the operating business
acquired from DNA Sciences, including retaining all of the current
customers as well as signing new agreements. The operation provides
GLP pharmacogenetic clinical services from a GLP-compliant and
CLIA-licensed facility in Research Triangle Park, NC. The services
include DNA purification and banking, sample anonymization and
management, and genotyping for clinical trials. The integration plan
included integrating employees, customers, systems, technology, and
sales and marketing.

* Genaissance acquired intellectual property for diagnosing Long QT
syndrome (LQT). LQT is caused by structural abnormalities in the
potassium and sodium channels of the heart, which predispose affected
persons to an abnormal heart rhythm (dysrrhythmia). Acquired LQT can
be the result of the administration of a medication. More than
50 approved prescription drugs, in various therapeutic classes, are
thought to prolong the QT-interval. Drug-induced LQT has led to the
withdrawal of such well-known drugs as the heartburn agent Propulsid(R)
and the antihistamine Seldane(R). Genaissance is currently marketing
to pharmaceutical companies the ability to include LQT genetics in drug
development and expects to launch a diagnostic test for diagnosing
familial LQT in the first quarter of 2004.

Additional Corporate Highlights

* Genaissance appointed Ben D. Kaplan to the position of Senior Vice
President and Chief Financial Officer (CFO). Mr. Kaplan was previously
Senior Vice President Finance and CFO at Ikonisys, Inc., an emerging
diagnostic company, and Vice President and CFO at Packard Bioscience
Company, where he was involved in all aspects of corporate
transactions, including the $750 million sale of the company to
PerkinElmer, as well as nine acquisitions over a four-year period. In
addition, Mr. Kaplan led Packard`s $100 million initial public offering
in April 2000 and $300 million corporate recapitalization.

* Genaissance sponsored the 6th Annual Pharmacogenetics and Medicine
Lectures at the Yale University School of Medicine. Janet Woodcock,
M.D., Director, Center for Drug Evaluation and Research, FDA, gave the
key note address. The FDA previously announced a broad initiative to
help make innovative medical technology, including pharmacogenomics,
available sooner and to reduce the costs of developing safe and
effective medical products. Later this year, the FDA is expected to
issue draft guidance for using pharmacogenomics. The FDA has also
scheduled a workshop for November 2003 on issues that are involved in
submitting pharmacogenomics information to the agency.


Genaissance will host a conference call and web cast to discuss events disclosed in this press release. The previously-announced call is scheduled for today at 11:00 a.m. Eastern Time. To participate in this call, dial 913-981-5542, confirmation code 589054, shortly before 11:00 a.m. A replay of the call will be available from 2:00 p.m. Eastern Time through 12:00 midnight on Tuesday, August 19, 2003. The replay number is 719-457-0820, confirmation code 589054. The web cast can be accessed at www.genaissance.com.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA-based diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the expected growth and development of Genaissance`s business, including revenue and operating expenses, expected financial performance, the demand for GLP services, the launch of a diagnostic test for familial LQT, and the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the endorsement by regulatory agencies and the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003 and our Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

[ZittrigeHand]

Press Release Source: Genaissance Pharmaceuticals, Inc.


Genaissance Pharmaceuticals and AstraZeneca Sign Pharmacogenomics Based Agreement
Thursday September 11, 7:30 am ET
- Agreement Continues the Commercialization of the STRENGTH Study -


NEW HAVEN, Conn., Sept. 11 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has entered into a licensing agreement with AstraZeneca PLC (NYSE: AZN - News) to utilize information generated from Genaissance`s Statin Response Examined by Genetic Haplotype Markers (STRENGTH) study. Under the terms of the agreement, AstraZeneca will receive non-exclusive access to the STRENGTH study database for research purposes for a limited period. This marks the second commercialization agreement related to the proprietary data generated in Genaissance`s STRENGTH study.
"We are pleased to enter into this new agreement with AstraZeneca," said Kevin Rakin, President and CEO of Genaissance. "Such agreements demonstrate our continued effort to commercialize and build on our internal programs such as STRENGTH."

The licensing arrangement is focused on proprietary data generated in the STRENGTH study. This study of more than 400 patients demonstrated that gene variations are associated with response to treatment with the statin class of drugs. Conducted over 16 weeks, the STRENGTH study prospectively analyzed for an association between an individual`s genetics and the clinical effectiveness of three statins (atorvastatin, pravastatin and simvastatin) in reducing LDL- cholesterol. Initial results of this study were presented at the 52nd Annual American College of Cardiology Scientific Session in March 2003.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA-based diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the expected growth and development of Genaissance`s business, including revenue, the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the endorsement by regulatory agencies and the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003 and our Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.






+ 38 %

[Neoe]

ZittrigeHand:

Ich denke wir wissen beide, dass das nur der Anfang war.
Die WIRKLICH GUTEN NEWS kommen innerhalb der nächsten 3-4 4 Monate: Mit den neuen FDA-Zulassungsvorschriften, der Einführung der LongQT-Diagnose und einigem mehr....

Jahresende: Kurs von 3-5 Dollar je nach Börsenentwicklung.

[Neoe]

OH GOTT, es ist passiert: WALLSTREET-ONLINE nimmt tatsächlich ein Unternehmen namens GENAISSANCE zur Kenntnis.

Die Meldung von W-O:AstraZeneca schließt Lizenzabkommen mit Genaissance

Das Biotechnologie-Unternehmen Genaissance Pharmaceuticals Inc., welches genetische Variationen erforscht, traf eine Vereinbarung mit der britischen AstraZeneca Plc.

Demnach darf Europas zweitgrößter Pharmakonzern Daten von Genaissance über Cholesterin-Medikamente nutzen. AstraZeneca erhält einen nicht-exklusiven Zugang zu einer Studie, die unterschiedliche Reaktionen von Patienten auf eine Behandlung mit Medikamenten der Statin-Klasse zeigt.

Mitte August erhielt AstraZeneca die Zulassung der U.S. Food and Drug Administration für seinen Cholesterin-Senker Crestor. Analysten prognostizieren für das Arzneimittel der Statin-Klasse jährliche Peak Sales von bis zu 3 Mrd. Dollar.

Die Aktien von Genaissance stiegen an der NASDAQ bisher um 32,0 Prozent und notieren derzeit bei 1,98 Dollar.

[ZittrigeHand]

knapp 800 k aktien bis jetzt gehandelt

neoe
das teil müsste eigentlich jetzt schon bei 3-4$ stehen.
éarnings und verräge werden immer besser.........

na ja....börse eben

[ZittrigeHand]

REVENUES: 1999=$680,000.00
2000=$753,000.00
2001=$5,300,000.00
2002=$8,100,000.00
2003 projected earning $10 to 12 million

For the six months ended June 30, 2003, revenues grew 39% to $5.3 million
As of year June 2003, Genaissance had cash, cash equivalents and marketable securities totaling $23.3 million.

SHARES OUTSTANDING 22.8 MILLION

Genaissance Pharmaceuticals And AstraZeneca Sign Pharmacogenomics Based Pact
Thursday September 11, 7:45 am ET

On May 15, 2003, Genaissance Pharmaceuticals acquired certain assets and liabilities of DNA Sciences, Inc. for $1,778,000, inclusive

Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has entered into a non-exclusive license agreement with BD (Becton, Dickinson and Company)
Jan 24, 2003

Genaissance Pharmaceuticals, Inc. and Bayer Diagnostics Sign Pharmacogenomics Collaboration and License Agreement
Jan 21, 2003

Genaissance Pharmaceuticals, Inc. Enters Into HAP Technology License Agreement With Millennium Pharmaceuticals
Jan 07, 2003

Genaissance Pharmaceuticals, Inc. Enters into a Pharmacogenomics Based Agreement with Pharmacia
Dec 17, 2002

Genaissance Pharmaceuticals, Inc. Achieves Milestone in Pharmacogenetics Alliance With Johnson & Johnson Pharmaceutical Research & Development
Dec 05, 2002

Genaissance Pharmaceuticals, Inc. Management Team Purchases Company Shares on Open Market
Aug 29, 2002

Genaissance Pharmaceuticals, Inc. Issues FY 2002 Guidance, Cuts Workforce by 20%
Aug 05, 2002

Genaissance Pharmaceuticals, Inc. Discovers Genetic Markers Associated With Response To Statin Drugs in Initial Analysis of STRENGTH I Clinical Study
Mar 26, 2002

Genaissance Pharmaceuticals, Inc. Signs Agreement with INTEC W&G Informatics Corporation to Market HAP Technology in Japan
Feb 06, 2002

Genaissance Pharmaceuticals, Inc. Confirms 2002 Guidance
Feb 01, 2002

Genaissance Pharmaceuticals, Inc. and AstraZeneca Sign Genomics Agreement
Dec 11, 2001

Genaissance Pharmaceuticals, Inc. Signs Pharmacogenomics Agreement with Pfizer
Oct 09, 2001

[Neoe]

ZittrigeHand:

Die News der Vergangenheit sind zwar eindeutig in ihrem Trend, lassen aber immer noch genug Ungewissheit, dass sogar ein einzelner großer Investor den Aktienpreis (an normalen Handelstagen) in jede gewünschte Richtung bewegen kann.

Das heisst, die Lösung dieses Problems wird ein dauerhaft hohes Volumen + das Loswerden der Leute die 2002 bei ca. 0,4$ reingekommen sind voraussetzen.

Die Frage ist nun: wann passiert das ?

Nochmal meine Annahme dazu:

Die FDA hat ganz klar eingeschwenkt und den Hauptzweifel an der gesamten Pharmacogenomics-Industrie ausgeräumt, indem sie Guidelines für Nov. 2003 ankündigte, die mindestens Richtlinien für diagnostische Tests, wenn nicht schon für die Medikamentenentwicklung vorgeben. Die FDA hat sogar schon durchblicken lassen, daß sie personalisierte Medizin in Zukunft zu Vorschrift machen wird.
Warum ? Weil die USA sonst unweigerlich von Billigmedikamenten vor allem aus Indien überschwemmt wird, die von auslaufenden Patenten profitieren. Das heisst der FDA wird nichts anderes übrig bleiben als die Messlatte höher zu legen, andernfalls werden Pfizer und Co. in Zukunft erheblich Marktanteile einbüßen und damit zum freien Sturzflug ansetzen.

Wenn dieser Event stattgefunden hat, wird GNSC sukzessive steigen und zu alledem ganz von alleine richtige Kooperationen bekanntgeben und nicht solche halbgaren Dinge wie gestern.


Wohlgemerkt ohne zu übertreiben:

Die Aktie diese Unternehmens wird in den nächsten Jahren definitiv einige tausend Prozent steigen, da es eine Schlüsselposition für die amerikanische und europäische Pharmaindustrie besetzt.
Genau zwei Punkte können diese Entwicklung stoppen:
1. Eine Übernahme 2. Eine Meinungsänderung der FDA.
Die Wahrscheinlichkeit, das 1. eintritt, dürfte bei 80-90%
liegen. Die Wahrscheinlichkeit, das 2. eintritt bei 1/1000.


Konkurrenzunternehmen mit vergleichbar wichtigen Forschungsergebnissen: DNAPrint Genomics, ansonsten keine Konkurrenz, die heute bereits ernsthaft zu bewerten ist.

[ZittrigeHand]

Press Release Source: Genaissance Pharmaceuticals, Inc.


Genaissance Reaches Milestone in CARING Study
Wednesday September 17, 7:30 am ET
- Study to Examine the Role of DNA Variation in Clozapine Safety -


NEW HAVEN, Conn., Sept. 17 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has reached enrollment goals in order to initiate HAP(TM) Marker discovery in its Clozapine and Agranulocytosis Relationships Investigated by Genetics (CARING) study. The CARING study will utilize Genaissance`s HAP(TM) Technology and expertise to examine patients who develop white cell depletion (agranulocytosis) in response to clozapine treatment. DNA from these patients will be studied to determine whether genetic commonalities exist that would help predict similar occurrences of clozapine-induced agranulocytosis in other patients. Initial results from the study are expected in 2004.
"Clozapine has long been accepted as one of the most effective medicines for treating schizophrenia but has had limited utilization due to the risk of inducing agranulocytosis," said John Kane, M.D., Chairman of the Department of Psychiatry at the Zucker Hillside Hospital, Professor of Psychiatry at Albert Einstein College of Medicine, and co-Chair of the CARING Steering Committee. "Currently, physicians who prescribe clozapine must submit blood monitoring information for each patient to a central registry for the duration of treatment. If a genetic test could be used to predict agranulocytosis, perhaps the need for frequent blood testing could be minimized."

"The goal of this study is to find genetic markers that can predict individuals who will develop this life-threatening complication as a result of being treated with clozapine," added Carol R. Reed, M.D., Vice President of Medical Affairs for Genaissance. "If these markers are identified, we believe they will not only benefit schizophrenia patients, but they will also pioneer a new approach to how safety is assessed in new and existing medicines."

[Neoe]

ZittrigeHand:

Ein Artikel, den ich bisher zuvor nirgendwo entdeckt habe. Es gibt wohl kein passenderes hundertstes Posting. Der Zeitplan hat sich wohl um ein Jahr verschoben, aber die Zahlen plus die kurzen Entwicklungszeiten lassen mich schon jetzt vor Vorfreude in die Luft springen. Eines Tages kommt es zu einer Pressemeldung und plötzlich wird die Welt sich damit befassen müssen, was hier bahnbrechendes vor der Tür steht. Zukünftig kommt KEIN MEDIKAMENT an den "Genetic Markers" vorbei. In zehn Jahren wird sich in keinem Medikament mehr ein Beipackzettel mit eventuelen Nebenwirkungen befinden und wir können uns ordentlich auf die Schenkel klopfen:


Genaissance Pharmaceuticals : First Drug Development Candidates

Company Leverages Technology Investment Into New Products That Combine Pharmaceuticals and Proprietary Genetic Markers

New Haven, CT, January 24, 2002 – Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today outlined its strategy for applying its proprietary HAP™ Technology to develop a product pipeline of "best in class" personalized medicines at the 4th Annual Personalized Medicine: Opportunities and Challenges for Commercialization conference in San Francisco, CA. Genaissance products, known as HAP™ Drugs, combine pharmaceutical compounds with genetic markers that define the patient population which responds best to the medication and has a superior safety profile. The first two product candidates are HAP™-Clozapine for schizophrenia and HAP™-Statin for cholesterol management. These internal HAP™ Drug development programs will complement existing business strategies focused on establishing technology and drug-specific partnerships with pharmaceutical and biotechnology companies.

"We are translating the advances made with our HAP™ Technology and clinical research programs into the development of pharmaceutical products," said Gualberto Ruaño, M.D., Ph.D., CEO of Genaissance. "Genaissance is now one of only a few companies with a product pipeline utilizing genomics technologies and is at the forefront of leveraging human gene variation data to develop new drugs."

HAP™ Drugs represent a significant business opportunity for Genaissance. The goal is to utilize the Company`s HAP™ Technology to create superior products from drugs that were previously undifferentiated, had an unpredictable safety profile, had a narrow therapeutic window or whose patent had expired. The Company`s drug development process starts with the identification of pipeline or off-patent compounds that meet the above criteria. The Company will then conduct Phase II-sized clinical association studies to identify the genetic marker(s) that are predictive of drug safety and efficacy. Compared to traditional drug development, the HAP™ Drug development strategy is a rapid, lower-risk process to select compounds for entry into late phase clinical trials. The Company may formulate certain drug candidates to further enhance their performance. Genaissance also has an active joint venture and in-licensing effort to identify pipeline products that may not be realizing their full potential.

"Genaissance is planning to use its technology platform to leapfrog some of the costly and time-consuming drug discovery and development steps," said Kevin Rakin, Genaissance President and CFO. "We believe that we have the ability to create substantial shareholder value by developing a series of proprietary, "best in class" products."

HAP™-Clozapine

Although highly effective, clozapine is restricted by its label to third-line therapy of schizophrenia at least in part because of the risk of agranulocytosis, a potentially life-threatening depletion of white blood cells. The need for repeated blood tests to monitor for the development of agranulocytosis results in poor patient compliance, restricts market share and limits sales to approximately $350 million in the U.S. Minimizing or eliminating the need for frequent blood monitoring by reducing the risk of agranulocytosis would enable many more patients to benefit from using clozapine. It is expected that development of HAP™-Clozapine will be initiated in the first quarter of 2002 with a study designed to identify the genetic marker(s) associated with agranulocytosis. Approximately 200 patient samples will be collected and analyzed over a nine month period. The funding of the study was previously included in the Company`s financial guidance provided for this year. If additional product milestones are met, it is expected that the development of HAP™-Clozapine could be completed in 2005. The antipsychotic market in the U.S. is projected to reach $8 billion by 2005.

HAP™-Statin

The planned HAP™-Statin will have a target profile of superior performance in changing the levels of biochemical markers related to the prevention, development and progression of atherosclerotic disease. Final product selection and a development timeline will be finalized once the study data from the STRENGTH I and II clinical trials are fully analyzed in the first half of 2002. If additional product milestones are met, it is expected that the development of HAP™-Statin could be completed in 2005. The U.S. statin market is expected to grow to $17 billion in 2005.

[Neoe]

Zwei sehr interessante Artikel:


1.

Pharmacogenomics Gets Clinical
By Jennifer Van Brundt
http://www.bettermanagement.com/library/library.aspx?library…
Happy Trials
The STRENGTH trial is Genaissance`s crown jewel, but the New Haven company has also conducted two other clinical studies analyzing drug responses. In these studies, too, the company claims that it has conclusively shown that HAP markers can identify patient populations with a defined drug response. "The STRENGTH study was special because of the sheer scale of the experiment. The other two internal studies were much smaller," Ruano said.
The company`s first clinical study, intended as a proof of principle, involved examining genomic variation in the beta2-adrenergic receptor, the target of the asthma drug albuterol (GlaxoSmithKline plc`s Ventolin), to ascertain whether it could use HAP markers or SNPs to define an asthma patient population that responded to the drug. The 121 asthmatic patients enrolled in the study varied in their responses to the drug; in fact, albuterol was clinically effective in only 40 percent of those patients. The researchers found that specific pairs of HAP markers in the receptor gene were carried by those patients who exhibited a positive drug response, and poor responders carried other specific pairs of markers. This correlation was statistically significant. By contrast, the company found that no individual SNP had equivalent predictive power.
Genaissance is currently recruiting patients for its CARING study, to identify HAP markers that define patients with schizophrenia who are most likely to develop agranulocytosis (a potentially life-threatening depletion of white blood cells) if treated with the schizophrenia drug clozapine. If the company succeeds in identifying these markers, it intends to line up a partner to commercialize them – either through a stand-alone diagnostic test or a test associated with a drug. Genaissance used the same sort of strategy early this year to parlay its findings from the STRENGTH trial into a commercialization deal with Bayer HealthCare LLC, which gets exclusive rights to develop a diagnostic and non-exclusive rights to develop drugs.
Boitechs Team Up
And, in another deal (of which Genaissance has many), Biogen Inc. will use Genaissance`s HAP technology to study the pharmacogenomic basis of patient variability in response to Amevive, Biogen`s newly approved biological therapy for moderate-to-severe psoriasis. As part of the January 2002 alliance, Biogen also gets a license to use those HAP markers that are shown to be predictive of response to Amevive to develop diagnostic tests for use in conjunction with its product marketing efforts.


2.

"The FDA has approved BIOGEN`s large scale manufacturing plant (LSM) in Research Triangle Park (RTP),NC, for commercial production of its chronic plaque PSORIASIS drug AMEVIVE. BIOGEN plans to use the LSM, which has 90,000 liters of bioreactor capacity, to manufacture future products in the company`s pipeline."...Contract Pharma, September 2003, page 85.



ZittrigeHand:

Wir werden leider bei 2 Dollar festgehalten, wenn ich bei Yahoo ins ASK schaue wird mir bei 2,00 jedesmal übel.

[Lars_78]

Hallo,

gestern war ja richtig was los, erst rauf dann massiv runter und dann wieder hoch....

Gibts dafür Gründe??

Lars

[Neoe]

Weiterhin gute Entwicklungen, die bei Genaissance vor sich gehen:



Press Release Source: Genaissance Pharmaceuticals, Inc.


Genaissance Appoints Karen A. Dawes to Board of Directors
Wednesday October 1, 7:30 am ET


NEW HAVEN, Conn., Oct. 1 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced the appointment of Karen A. Dawes to its Board of Directors, increasing the number of directors to seven.
"We are delighted to welcome Karen to our Board," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Karen is respected for her marketing acumen in the industry and was responsible for launching biological and small molecule products. We look forward to her providing counsel on commercial and strategic issues surrounding applications of our HAP(TM) Technology."

Ms. Dawes is currently Principal, Knowledgeable Decisions, LLC, a consulting group to biotech and emerging pharmaceutical companies. During her tenure in the pharmaceutical industry, Ms. Dawes held various commercial and strategic roles with Bayer Corporation, Wyeth Pharmaceuticals, Genetics Institute and Pfizer Inc. In her most recent role at Bayer, she was Senior Vice President, U.S. Business Group Head, where she led the U.S. pharmaceutical group. Ms. Dawes also serves on the Board of Directors of Protein Design Labs, Inc. (Nasdaq: PDLI - News). She earned Bachelors and Masters degrees from Simmons College as well as an M.B.A. from Harvard University.

"I am excited to join the Genaissance team," said Ms. Dawes. "Pharmacogenomics is rapidly becoming a mainstay of pharmaceutical development and marketing. Genaissance is clearly developing a leadership position in this field and I look forward to working with them."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

[Neoe]

52W HIGH: New 52-Wk High for GNSC @ $2.350 up11.90% [delayed]

Ridgeland, MS, OCT 02, 2003 (EventX/Knobias.com via COMTEX) -- This is the 1st 52 WEEK HIGH alert for GNSC in the past 7 calendar days.

The share price for Genaissance Pharmaceuticals, Inc. (NASDAQ NM: GNSC) reached a new 52-week high today, trading at $2.350, up $0.250 (11.90%) from its previous close of $2.100.

The Company`s previous 52-week high of $2.260 was set 21 days ago on September 11, 2003.

One year ago, the Company`s shares closed at $0.500. The price has climbed more than 370 percent since then.

At the time of this alert, the stock had traded 154,300 shares via 176 trades, 18.05% below it`s 20day average of 188,274 shares.

This new 52-week high currently puts the stock:

29.34% above its 20day Moving Average of $1.817

54.55% above its 50day Moving Average of $1.521

49.26% above its 100day Moving Average of $1.574

The Company last released news on October 01, 2003 (yesterday):

"Genaissance Appoints Karen A. Dawes to Board of Directors"

GENAISSANCE PHARMACEUTICALS, INC.

Engages in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills as a solution for improving the development, marketing and prescribing of drugs.


Schlusskurs 2.48 $ (+18%)

[Neoe]

Home > Archive > Aug 13, 2003 > Beyond the Blockbuster


GUEST COMMENTARY



Beyond the Blockbuster

The gap between scientific possibility and economic reality is a familiar story in the history of innovation, and we are seeing it now in the pharmaceutical industry. On one side, new genetic knowledge is laying the groundwork for personalized medicine — highly effective drugs developed for small patient populations defined by genetic profiles.

But drug company executives, facing soaring costs and other hurdles, have pinned their growth strategies on new blockbuster drugs (meaning annual sales of $1 billion or more). Such drugs, increasingly rare, must be usable by large patient populations and be effective against widespread illnesses that require long-term medication, such as cancers or chronic degenerative diseases.

What targeted drugs would lose in market size, they would make up for in effectiveness. While blockbusters work adequately for most patients, genetically targeted drugs would work very well for virtually all the members of smaller niche populations. Personalized drug treatment would improve patient care, of course, but it would require a major adjustment for drug companies wedded to the blockbuster model. Furthermore, would, or could, consumers or insurers pay extra for a more effective product?

So why not just apply new technology to produce drugs to fit the customer, as Dell does with made-to-order computers? In theory, this is not as wild an idea as it may sound. The convergence of genomic data and computing power should make drug discovery faster and less expensive, with fewer false starts. The ability to identify those genetic features that determine a patient`s propensity to certain diseases and individual responses to potential drugs should streamline the list of drug candidates before any testing, human or animal, needs to be done.


Pharmacogenomics Can Help
The greatest impact of such data sifting would be in the early stages of drug development. It would probably not be as directly effective against a faster-growing problem: the costs of clinical trials later in the development process. In 2001, the Tufts Center for the Study of Drug Development reported that clinical trials costs climbed 11.8 percent per year (adjusted for inflation) from 1987 to 2000 — more than a fourfold increase. The length of clinical trials also continues to rise. This year, Tufts reported the average clinical phase time for new biopharmaceuticals rose 137 percent — from 31 months (between 1982 and 1989) to 74 months (between 2000 and 2002).

Unless a way is found to leverage technology and make trials more focused, the exorbitant cost of getting a drug to market will continue to drive big drug companies toward blockbusters. These firms will align their resources toward the big payoffs and away from personalized drugs. Smaller firms might continue to thrive by offering small-market drugs that the big pharmaceutical firms no longer want in their portfolios. But most of them will have trouble finding the capital to develop true breakthrough drugs from genomic data.

Solving this dilemma isn`t simply a matter of reforming the FDA approval process or pushing the right technological buttons. Both are crucial, but neither one is a magic bullet. The FDA approval process is bound to be rigorous as long as the public cares (as it must) about drug safety. And there is only so much that can be learned about safety before a drug is tried on humans.

However, genomics technology has the potential to save money in the pretrial stages by focusing candidate compound selection. By identifying which subjects would be most likely to experience beneficial results and avoid adverse reactions, genomics can help reduce large, broad-population testing, which is currently one of the biggest drains on pharmaceutical R&D budgets.

On the regulatory side, the greatest need is for better coordination and sharing of knowledge between drug companies and the FDA. This is especially true at the early stages, when the drug firms are identifying the most promising compounds and starting to design clinical trials. FDA Commissioner Mark McClellan wants to give drug developers earlier feedback on candidates and clinical trial design and also clarify the FDA`s standards and expectations for approval. (See "Remaking the FDA in McClellan`s Image," page 48.)

The agency is starting to develop standards and techniques for pharmacogenomics, which should greatly improve the process of developing drugs for rare conditions and small populations. But pharmacogenomics needs FDA approval guidelines to get off the ground commercially. By following through on these initiatives, the FDA can help this new science reach its full potential, which will benefit not only the drug industry but, of course, the public as well.

Right now, there`s a crying need in the drug industry for such innovation in development. How fast will the necessary changes occur? That depends on the sense of urgency in the industry. However, the big pharmaceutical firms are investing in relevant genomics technology, and the FDA would not go to the trouble of developing new standards if it did not believe pharmacogenomics is here to stay.

Pharmacogenomics and blockbusters are not mutually exclusive. The new science may be producing blockbusters of its own in a few years. But personalized medicine will also be an essential part of the future product mix, because patients and physicians will demand it. If the big pharmaceutical companies decide to embrace it wholeheartedly, then we might see remarkably fast progress. We may continue to see inertia and indecision, too, but probably not for very long. The potential of pharmacogenomics is just too great to stay bottled up.



John Rhodes ([e-mail]) is the managing partner for Deloitte & Touche`s Life Sciences Practice.

[Neoe]

Neue Website mit etlichen interessanten Ausführungen:

http://www.genaissance.com

[Preacher]

Hi,
da geht doch noch was bei Genaissance; Chart schaut aus wie bei Genaera (nur mit ein paar Monaten Verzögerung), die sind von 20 Cent auf 5,50 gelaufen. Tief von genaissance war bei etwa 45 Cent, warum sollen in ein paar Monaten nicht die 10 Dollar fallen? Aber immer schön langsam
Gruß Preacher

[ZittrigeHand]

gestern up mit einem schönen volumen
liegt irgendwas im busch,ich las von div.konferenzen

[DJMassiveBlast]

3,10 $

[DJMassiveBlast]

November 18, 2003 07:33

Genaissance Pharmaceuticals Expands Into Consumer Market with a HAP(TM) Technology License Agreement with Sciona Limited
Agreement Targets Integrating the Use of Genetic Variation Into Wellness Products

NEW HAVEN, Conn., Nov 18, 2003 /PRNewswire-FirstCall via Comtex/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has licensed its HAP(TM) Technology to Sciona Limited for use in the development and marketing of consumer products. Under the terms of the multi-year agreement, Genaissance will have rights to support Sciona`s pharmacogenomic research and customer genotyping. In exchange for a license to its HAP(TM) Technology, Genaissance obtained a 30% fully-diluted equity position in Sciona, a private company based in the United Kingdom. Genaissance will also receive royalties on any products that are developed by Sciona, which incorporate Genaissance`s HAP(TM) Technology.

"We are pleased to enter into this agreement because Sciona is a leader in the emerging market of integrating genetic variation into wellness products," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We have developed a close working relationship with Sciona over the past year by assisting them in developing and launching their first product into the U.S. market for customizing diet and nutrition. This agreement continues the commercialization of our HAP(TM) Technology in a variety of new markets."

"We believe that Genaissance`s HAP(TM) Technology will have profound implications for the development of customized personal care and nutritional products," said Dr. Chris Martin, Chief Executive Officer of Sciona Limited. "We introduced our first product in 2002 and by using Genaissance`s technology, we believe that we can help companies create a new generation of innovative nutritional and personal care products."

About Genaissance

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

About Sciona

Sciona Limited, a privately held genetics company, is a world leader in developing tools and services that enable companies to customize personal care and nutritional products based upon an individual`s genetic profile. Sciona has agreements for using its first product, which customizes diet and nutritional product choice. Visit the company`s website at www.sciona.com.

[Neoe]

Nächstes Jahr steigt Genaissance in eine andere Liga auf....wetten ?!?

Noch ist das Puzzle nicht ganz gelegt, aber wer sich mit Genaissance befasst hat, wird von wohl schon von enormen Kurssteigerungen träumen.

[Neoe]

Wer genauer wissen möchte, was in nächster Zeit passiert, sollte sich folgende Präsentation anschauen. Besonders interessant finde ich "Slide 7"; hier sind einige Logos von Partnern zu sehen: Bisher ist mir nichts zu Ohren gekommen, bezüglich einer Partnerschaft mit ELI LILLY und dem NATIONAL INSTITUTE OF HEALTH, diese Logos sind hier aber eindeutig zu erkennnen !!!! NOCH MEHR GUTE NEWS ????


http://www.shareholder.com/visitors/event/build2/launchpad.c…

[derschweizer]

Die machen Nägel mit Köpfen!
Wieder ein neues Lizenzabkommen, diesmal mit Novo Nordisk.
Einem Big Player im Bereich Diabetis Erkrankungen.
Nächstes Jahr schafft die HAP (TM)Technologie den entgültigen Durchbruch und dann ..... gehts ab!

Grüße an alle Genaissance investierten

[Kaeptn_Hirni]

Press Release Source: Genaissance Pharmaceuticals, Inc.; Lark Technologies, Inc.


Genaissance Pharmaceuticals, Inc. to Acquire Lark Technologies, Inc.
Friday December 19, 6:30 am ET
- Acquisition Complements Genaissance`s Pharmacogenomic Base Business -
- Significantly Increases Revenues; Adds Profitable Operation and UK Facility -


NEW HAVEN, Conn., and HOUSTON, Dec. 19 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) and Lark Technologies, Inc. (OTC Bulletin Board: LRKT - News) today announced that they have signed a definitive agreement whereby Genaissance will acquire Lark in an all stock transaction. Under the terms of the agreement, Genaissance will issue approximately 6.7 million shares of its common stock to Lark`s stockholders, who will receive 1.81 shares of Genaissance`s common stock for each share of Lark`s common stock that they own, and will assume outstanding Lark options exercisable for an aggregate of approximately 1.5 million shares of Genaissance common stock. The transaction is valued at approximately $19.9 million, based on the closing price of Genaissance`s common stock of $2.99 per share on December 18, 2003.
ADVERTISEMENT


Following the transaction, Genaissance expects to have projected pro-forma revenues in excess of $25 million for calendar 2004, a substantially reduced operating loss, an expanded pharmacogenomic service and technology portfolio with facilities in the U.S. and England and additional financial resources to advance the development of pharmacogenomic based proprietary products. Dr. Carl Balezentis, President and Chief Executive Officer of Lark, will join Genaissance as Senior Vice President and President, Lark Technologies.

Lark, headquartered in Houston, Texas, with European operations located near Cambridge, England, offers Good Laboratory Practices (GLP) compliant and research genomic services for use in pharmaceutical, diagnostic and agricultural product research and development. For the nine months ended September 30, 2003, Lark reported revenues of $6.8 million, net income of $1.2 million and operating income of $1.6 million.

"The acquisition of Lark is an exciting next step in the execution of our strategy to build a profitable base services business while developing proprietary products based on our HAP(TM) Technology," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "The addition of Lark will provide us with access to a broader client base, a GLP sequencing capability that complements our existing GLP genotyping ability, a strong and growing European operation and an experienced team focused on profitable revenue generation. Most importantly, as we look forward, a profitable base services business will generate additional funds for the development of proprietary diagnostic and pharmaceutical products. I am also very pleased to welcome Dr. Carl Balezentis and his team to Genaissance."

The transaction has been approved unanimously by both Boards of Directors and is subject to shareholder approval by both companies and other customary closing conditions. The transaction is expected to close in the first half of 2004. The dates of special stockholder meetings for shareholders of Lark and Genaissance will be announced at a later date.

"The combined company`s capabilities will provide the pharmaceutical industry a pharmacogenomic solution spanning early stage research through clinical development and commercialization," said Carl W. Balezentis, Ph.D., President and Chief Executive Officer of Lark Technologies. "By becoming part of Genaissance, we expect to grow significantly our combined business through additional product offerings, cross selling of services and technologies and the ability to partner on specific product development opportunities. We are especially excited about the existing and potential programs for product development at Genaissance and the value that our shareholders may derive by participating in the further development and commercialization of these pharmacogenomic product programs."

Legg Mason Wood Walker, Incorporated and EMA Partners, LLC served as financial advisors to Genaissance in the transaction and Southwest Securities, Inc. served as financial advisor to Lark Technologies.

About Lark Technologies

Lark Technologies, Inc., based in Houston, Texas, offers genomic services for use in pharmaceutical, diagnostic and agricultural product research and development. These services include genomic data management, microarray support, quantitative PCR, genotyping, genetically-modified organism testing, and a battery of other molecular biology services which support researchers in the pharmaceutical, biotechnology and academic sectors in their attempt to understand the mechanisms of disease and to discover and develop new drugs. Visit the company`s website at www.lark.com.

About Genaissance

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA- based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

Genaissance plans to file with the SEC a registration statement on Form S-4 in connection with the transaction and Genaissance and Lark Technologies plan to file with the SEC and mail to their respective stockholders a joint proxy statement/prospectus in connection with the transaction. The registration statement and the joint proxy statement/prospectus will contain important information about Genaissance, Lark Technologies, the transaction and related matters. Investors and security holders are urged to read the registration statement and the joint proxy statement/prospectus carefully when they are available.

Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by Genaissance and Lark Technologies through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus from Genaissance by contacting Ms. Marcia Passavant or from Lark Technologies by contacting Ms. Jaime Thomas.

Genaissance and Lark Technologies, and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement. Information regarding the special interests of the directors and executive officers of Genaissance and Lark Technologies in the transaction described herein will be included in the joint proxy statement/prospectus.

Additional information regarding Genaissance`s directors and executive officers is contained in Genaissance`s Form 10-K for the year ended December 31, 2002, and its proxy statement dated April 21, 2003, which are filed with the SEC. As of December 15, 2003, Genaissance`s directors and executive officers beneficially owned approximately 1,037,035 shares, or 4.46%, of Genaissance`s outstanding common stock. Information regarding Lark Technologies` directors and executive officers is contained in Lark Technologies` Form 10-KSB for the year ended December 31, 2002, which is filed with the SEC. As of December 15, 2003, Lark Technologies` directors and executive officers beneficially owned approximately 962,176 shares, or 26.14%, of Lark Technologies` outstanding common stock.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including statements about the expected growth and development of Genaissance`s business and the combined company`s future financial and operating results, the timing, effects and any synergies that may result from the proposed acquisition, the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs and to detect associations between clinical outcomes and genetic variation. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the possibility that the information and estimates used to predict anticipated revenues and cost savings were not accurate, failure of the acquisition to be accretive in a timely manner, difficulty integrating operations, risks associated with the acquisition as well as transaction costs, failure to obtain expected synergies, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in Genaissance`s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2003, and Lark Technologies` Form 10-KSB filed with the Securities and Exchange Commission on March 31, 2003, and in other filings the parties make with the SEC from time to time. The forward-looking statements contained herein represent the judgment of Genaissance and Lark Technologies, as the case may be, as of the date of this release. Genaissance and Lark Technologies disclaim any obligation to update any forward-looking statement.




--------------------------------------------------------------------------------
Source: Genaissance Pharmaceuticals, Inc.; Lark Technologies, Inc.

[Kaeptn_Hirni]

wollen mal hoffen das es was bringt.

[Kaeptn_Hirni]

Here is the latest information, the big question here is, with the combo of all three companies, are we truly looking at a DNA POWER HOUSE?

REVENUES: 1999=$680,000.00
2000=$753,000.00
2001=$5,300,000.00
2002=$8,100,000.00
2003 projected earning $10 to 12 million

For the six months ended June 30, 2003, revenues grew 39% to $5.3 million
As of year June 2003, Genaissance had cash, cash equivalents and marketable securities totaling $23.3 million.

SHARES OUTSTANDING 22.8 MILLION

Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Novo Nordisk
December 18, 2003 08:01

Genaissance Pharmaceuticals and INTEC Web and Genome Informatics Corporation Announce Commercialization Progress in Japan
December 04, 2003 07:34

Genaissance Pharmaceuticals Expands Into Consumer Market with a HAP(TM) Technology License Agreement with Sciona Limited
November 18, 2003 07:33

Genaissance Pharmaceuticals And AstraZeneca Sign Pharmacogenomics Based Pact
Thursday September 11, 7:45 am ET

On May 15, 2003, Genaissance Pharmaceuticals acquired certain assets and liabilities of DNA Sciences, Inc. for $1,778,000, inclusive

Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has entered into a non-exclusive license agreement with BD (Becton, Dickinson and Company)
Jan 24, 2003

Genaissance Pharmaceuticals, Inc. and Bayer Diagnostics Sign Pharmacogenomics Collaboration and License Agreement
Jan 21, 2003

Genaissance Pharmaceuticals, Inc. Enters Into HAP Technology License Agreement With Millennium Pharmaceuticals
Jan 07, 2003

Genaissance Pharmaceuticals, Inc. Enters into a Pharmacogenomics Based Agreement with Pharmacia
Dec 17, 2002

Genaissance Pharmaceuticals, Inc. Achieves Milestone in Pharmacogenetics Alliance With Johnson & Johnson Pharmaceutical Research & Development
Dec 05, 2002

Genaissance Pharmaceuticals, Inc. Management Team Purchases Company Shares on Open Market
Aug 29, 2002

Genaissance Pharmaceuticals, Inc. Issues FY 2002 Guidance, Cuts Workforce by 20%
Aug 05, 2002

Genaissance Pharmaceuticals, Inc. Discovers Genetic Markers Associated With Response To Statin Drugs in Initial Analysis of STRENGTH I Clinical Study
Mar 26, 2002

Genaissance Pharmaceuticals, Inc. Signs Agreement with INTEC W&G Informatics Corporation to Market HAP Technology in Japan
Feb 06, 2002

Genaissance Pharmaceuticals, Inc. and AstraZeneca Sign Genomics Agreement
Dec 11, 2001

Genaissance Pharmaceuticals, Inc. Signs Pharmacogenomics Agreement with Pfizer
Oct 09, 2001

[Neoe]

Nächstes Jahr rund 25 Millionen Umsatz und einer nach der Verwässerung bei etwa 90 Millionen Dollar liegenden Marktkapitalisierung.

Mag sich erst mal nach hoher Marketcap anhören, ist es aber nicht, da Genaissances Umsätze in einer Industrie entstehen, die eigentlich noch gar nicht richtig existiert, die Kundenliste beantwortet dann noch die restlichen Fragen, falls einer Zweifel hat.

Zudem wundere ich mich, dass von der Biogen-Kooperation nichts mehr zu hören ist. Da sie nach wie vor mit Genaissance arbeiten, gehe ich davon aus, dass hier vielleicht auf Top-Secret umgestellt wurde, denn eigentlich sollte 2004 ein Diagnostik-Produkt für Amevive fertiggestellt werden. Im Gegensatz zu früher, habe ich hier in letzter Zeit keine Infos mehr zu Gesicht bekommen.
Hier liegt einiges an unbestimmtem Umsatzpotential begraben, mal sehen wie es weitergeht.

[Neoe]

Wunderbare Nachrichten:


Genaissance Pharmaceuticals Analyzed Samples for United States Department of Agriculture in Mad Cow Disease Investigation
Friday January 9, 7:01 am ET
- Opportunity for Entry into Animal DNA Testing Market -


NEW HAVEN, Conn., Jan. 9 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) announced today that it had completed an analysis of DNA samples for the United States Department of Agriculture (USDA) as part of the USDA`s effort to trace the origin of the animal infected with bovine spongiform encephalopathy or Mad Cow disease.
"We were honored that the USDA asked us to analyze these very important samples," said Gerald F. Vovis, Ph.D., Executive Vice President and Chief Technology Officer of Genaissance Pharmaceuticals. "We had our personnel standing by to receive the samples when they arrived by courier and then worked around the clock to ensure that the results were available as rapidly as possible."

"We see the use of DNA testing for animal identity and traceability as a new market opportunity for us and another step in the execution of our strategy to build a profitable base services business while developing proprietary products based on our HAP(TM) Technology," Dr. Vovis continued. "We believe that we have the experience to be a major player in this arena because we have an accredited genotyping laboratory that has a high-throughput process for analyzing DNA, including a proprietary laboratory information management system, the necessary robotics and microarray instrumentation. During the past year, we used this platform to generate over 8,000,000 DNA analysis results for our customers."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

[Kaeptn_Hirni]

TSCHAKKA......here we go

[tui66]

keiner da zum mitfeiern?
mal sehen ob nochmal ein Endspurt kommt!

[Kaeptn_Hirni]

*feier

[tui66]

3,74$

[Kaeptn_Hirni]

1,4 mill sharés / +18%

[Kaeptn_Hirni]

3,33$

122

[tui66]

http://www.usa-aktienprofi.de/realtime.htm

schau mal 3,74 RT!

[Kaeptn_Hirni]

hm....

[Kaeptn_Hirni]

1,750,081 shares / +30%

[Kaeptn_Hirni]

mist.......war wohl nur ein kurzer anstieg.....BSE verseucht

[tui66]

Korrektur beendet

[chini]

Korrektur beendet, die Party geht weiter ! Seht selbst !

[Kaeptn_Hirni]

heute momentan über 4$

goooo GNSC....gooooooooooo

[derschweizer]

So, die Woche ist für GNSC gelaufen. Schlusskurs 3,66 US$.
Die 4 US$ Marke wurde mehrmals angetestet und auch geknackt. Leider, oder eigentlich logisch setzten Gewinnmitnahmen ein. Man darf nicht vergessen, dass die Aktie in den letzten Monaten schon 100% zugelegt hat. Nächste Woche erfolgt ganz sicher ein neuer Angriff. Sollte dieser gelingen und die 4 US$ nachhaltig überschritten werden, ist der Weg nach oben frei. Ich drücke für alle investierten die Daumen.

Viele Grüße

KS

[derschweizer]

Der Angriff auf die 4 US$ ist in vollem Gange. Zur Zeit 4,03 + 5,3% bei hohem Volumen. Die Gewinnmitnahmen sind verdaut, schließt GNSC über dem Widerstand von 4,10 US$ geht es Morgen weiter aufwärts. Das Tal der Tränen ist hoffentlich durchschritten. Die Zahlen kommen am 12.02.02!

Grüße derschweizer

[derschweizer]

Handelsschluss + 7,8% / 4,13US$, nahe 52 Wochen Hoch (4,20) Jetzt bin ich auf Morgen gespannt!

Eine schöne Woche

derschweizer

[MrRipley]

Mitte August erhielt AstraZeneca die Zulassung der U.S. Food and Drug Administration für seinen Cholesterin-Senker Crestor. Analysten prognostizieren für das Arzneimittel der Statin-Klasse jährliche Peak Sales von bis zu 3 Mrd. Dollar.


Angesehen davon, dass die Cholesterinlüge existiert
keine schlechte Nachricht.

Auch mit Lügen kann man viel Geld verdienen...

[Neoe]

Endlich mal wieder BIG NEWS, wenn auch so erwartet:

Genaissance Pharmaceuticals and Lark Technologies Receive Shareholder Approval For and Close Merger
Thursday April 1, 4:14 pm ET
- Combined Entity Expands Genaissance`s Pharmacogenomic Base Business and Global Presence -


NEW HAVEN, Conn., April 1 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) and Lark Technologies, Inc. (OTC Bulletin Board: LRKT - News) today announced that they closed the merger of Lark Technologies with and into a wholly owned subsidiary of Genaissance following approval of the merger by the stockholders of each of the two companies. The terms of the Agreement and Plan of Merger include the exchange of each outstanding share of Lark Technologies common stock for 1.81 shares of Genaissance common stock.
"I would like to welcome Lark shareholders and employees to Genaissance," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "The acquisition represents another step in the execution of our strategy to build a profitable base services business while developing proprietary products based on our HAP(TM) Technology. We now have access to a broader client base, additional GLP services, a strong and growing European operation and an experienced team focused on profitable revenue generation. In his new position, Dr. Carl Balezentis will head the effort to grow this profitable base services business, generating additional funds that will be available for the development of proprietary diagnostic and pharmaceutical products."

"Our entire team is excited to be a part of Genaissance," said Carl Balezentis, Ph.D., Senior Vice President of Genaissance and President of Lark. "We look forward to telling our combined customer base that we can provide one stop shopping for all of their DNA analysis needs."






Und hier nochmal zum nachschauen, was sich GNSC schönes eingekauft hat:


Lark Technologies Inc. Reports Record Revenue and Net Income for the Year Ended 2003
Tuesday March 30, 5:46 pm ET


HOUSTON--(BUSINESS WIRE)--March 30, 2004--Lark Technologies Inc. (OTCBB:LRKT - News) reported record revenue and net income of $9,028,382 and $1,422,343 or $0.39 per share for the twelve months ending December 31, 2003 as compared to revenue and net income of $6,692,305 and $724,949 or $0.20 per share for the same period in 2002.
Revenue and net income for the quarter ended December 31, 2003 increased 31% and 196%, respectively to $2,269,894 and $229,378 or $0.06 per share, compared to revenue of $1,728,619 and net income of $77,522 or $0.02 per share for the same period in 2002. The revenue growth during the quarter over the comparable period in 2002 was the result of increased sales in most product lines, including areas relating to genomic DNA sequencing, with the fastest growth occurring in the UK custom sequencing. "In spite of the fact that we no longer had available federal net operating tax loss carryforwards, coupled with significant expenses associated with the pending merger with Genaissance Pharmaceuticals Inc., we posted a very solid fourth quarter," said Chief Executive Carl W. Balezentis, Ph.D.

Commenting on the overall results of 2003 and outlook for 2004, Lark Technologies Inc. Chief Executive Officer Carl W. Balezentis, Ph.D. said, "I am extremely pleased with the progress we have made over the past two and one half years in terms of fiscal stability and revenue growth. We are reporting our ninth consecutive profitable quarter, concluding with record revenue and net income for the year. We look forward to the opportunities and challenges we face in 2004 as we look to aggressively grow the service business following our merger with Genaissance."

Lark Technologies Inc., based in Houston, Texas, offers genomic services for use in pharmaceutical, diagnostic and agricultural product research and development. These services include genomic data management, microarray support, quantitative PCR, differential display, genotyping, genetically-modified organism testing, and a battery of other molecular biology services which support researchers in the pharmaceutical, biotechnology and academic sectors in their attempt to understand the mechanisms of disease and to discover and develop new drugs. Lark`s stock is quoted on the OTC Bulletin Board under the symbol "LRKT.OB" On December 18th, 2003, the Company agreed to merge with a subsidiary of Genaissance Pharmaceuticals Inc., subject to shareholder approval at a meeting set for April 1, 2004.

[Rente mit 40]

Was habt ihr da schönes eingekauft. Ich musste meine schönen Lark Aktien geben um diesen GNSC Mist zu bekommen. Naja da wollen wir mal sehen ob die jemals Gewinne machen wie Lark seit 11 Quartalen. Ich hatte mich strikt gegen den Merger ausgesprochen.

[Neoe]

Rente:

Ab 2005 sind Gewinne angesagt. Mit dem LQT-Test wird GNSC den Break-Even schaffen, der wird bereits im Mai vorgestellt und eingeführt.

[Neoe]

Genaissance Pharmaceuticals Signs Amendment to License Agreement for Patents on Genes Associated With Sudden Cardiac Death Syndromes
Thursday April 29, 7:10 am ET
Simplifies Royalty Structure and Extends License Rights to Patent Estate


NEW HAVEN, Conn., April 29 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) announced today that it has signed an amendment to its license agreement with the University of Utah and Yale University, under which Genaissance has certain rights to a patent estate of more than 50 issued and pending patents in the United States and other countries relating to five cardiac ion channel genes associated with Long QT, Brugada and related syndromes. Genaissance acquired the license agreement in May 2003 as part of its acquisition of substantially all of the assets of DNA Sciences, Inc. The amendment will simplify the royalty structure for the genetic test for cardiac ion channel mutations, which Genaissance currently expects to launch in May at HEART RHYTHM 2004, the Heart Rhythm Society`s 25th Annual Scientific Sessions, as well as certain other genetic tests and products covered by the license agreement. The amendment also extends Genaissance`s license rights to the patent estate, including Genaissance`s right to grant sublicenses to companies seeking to use these genes in certain research applications.
ADVERTISEMENT


"We intend to use these extended patent rights to help us build a pharmacogenomic franchise around the genetics of cardiac ion channel mutations," said Richard S. Judson, Ph.D., Senior Vice President and Chief Scientific Officer of Genaissance. "Our long-term goal is to bridge our knowledge of Long QT Syndrome to drug-induced QT prolongation, which has led to the withdrawal of important and well known drugs from the market."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

[Neoe]

Genaissance Pharmaceuticals Reports First Quarter Results for 2004
Tuesday May 11, 7:30 am ET
- Quarter Highlighted by Acquisition of Lark Technologies and Preparation for Launch of the FAMILION(TM) Test, a Genetic Test for Cardiac Ion Channel Mutations -


NEW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today reported its financial results for the first quarter ended March 31, 2004.
For the three months ended March 31, 2004, revenue increased 74% to $3.7 million, compared to revenue of $2.1 million for the three months ended March 31, 2003, primarily as a result of increased revenues from GLP-compliant services and licenses to data from Genaissance`s HAP® Database. Operating expenses for the three months ended March 31, 2004, were $8.2 million, compared to operating expenses of $6.8 million for the three months ended March 31, 2003. The increase in operating expenses was primarily attributable to the cost of sales related to GLP-compliant services. For the three months ended March 31, 2004, Genaissance`s net loss attributable to common stockholders was $4.8 million, or $0.21 per share, compared to a net loss of $4.7 million, or $0.21 per share, for the three months ended March 31, 2003.

As of March 31, 2004, the Company had cash, cash equivalents and marketable securities totaling $11.4 million.

Recent corporate highlights include:
* Genaissance closed the merger of Lark Technologies with and into a
wholly-owned subsidiary of Genaissance, following approval of the
merger by the stockholders of both companies. The acquisition
represents another step in the execution of the Company`s strategy to
build a profitable base services business while developing proprietary
products based on Genaissance`s HAP(TM) Technology. Genaissance now
has access to a broader client base, additional GLP services, a strong
and growing European operation and an experienced team focused on
profitable revenue generation.

* Genaissance completed all pre-commercialization activities for the
launch of its genetic test for cardiac ion channel mutations, the
FAMILION(TM) Test. The test is designed to detect mutations
responsible for causing Familial Long QT and Brugada Syndromes, two
causes of sudden cardiac death. Genaissance currently expects to
launch the FAMILION(TM) Test in May at HEART RHYTHM 2004, the Heart
Rhythm Society`s 25th Annual Scientific Sessions and will process the
samples in its CLIA-licensed facility in New Haven, CT.

* Genaissance signed agreements to further its goal of developing a
pharmacogenomic franchise around the genetics of cardiac
channelopathies. As part of these agreements, Michael J. Ackerman,
M.D., Ph.D., Associate Professor at the Mayo Clinic College of
Medicine and Director of the Long QT Syndrome Clinic, and Arthur J.
Moss, M.D., Professor of Medicine at Rochester University, will serve
on Genaissance`s Advisory Board. The agreements were with:

* The University of Rochester and the Mayo Foundation for Medical
Education and Research, under which Genaissance obtains access
to expertise, materials, information and intellectual property
for use in developing and launching tests for cardiac
conditions; and

* The University of Utah and Yale University, under which
Genaissance has extended certain rights to a patent estate of
more than 50 issued and pending patents in the United States
and other countries relating to five cardiac ion channel genes
associated with Long QT, Brugada and related syndromes.

* Genaissance completed an analysis of DNA samples for the United States
Department of Agriculture (USDA) as part of the USDA`s effort to trace
the origin of the animal infected with bovine spongiform
encephalopathy or Mad Cow disease.


"We have strengthened our base services business through our recent acquisition of Lark and continue to move our proprietary pipeline closer to commercialization," said Kevin Rakin, President and Chief Executive Officer of Genaissance. "This month, we expect to launch the FAMILION(TM) Test, our first marketed molecular test. Our goal is to bridge our genetic knowledge of familial Long QT to drug-induced QT prolongation, which has led to the withdrawal of important and well-known drugs from the market."

OUTLOOK:

For the fiscal year 2004, after giving effect to the Company`s acquisition of Lark Technologies on April 1, 2004, Genaissance expects:

* Revenues to be in excess of $25 million;

* Operating expenses to be under $37 million, including approximately
$6 million of non-cash expenses; and

* Net loss attributable to common stockholders to be between $14 and
$15 million, including total non-cash charges of $7 million.


Genaissance will host a conference call and web cast to discuss events disclosed in this press release. The previously-announced call is scheduled for today at 11:00 a.m., Eastern Time (ET). To participate in this call, dial 719-457-2633, confirmation code 193643, shortly before 11:00 a.m. A replay of the call will be available from 2:00 p.m. ET through midnight Monday, May 17, 2004. The replay number is 719-457-0820, confirmation code 193643. The web cast can be accessed at www.genaissance.com.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA- based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut. Visit the company`s website at www.genaissance.com.

This press release contains forward-looking statements, including statements about the future financial results of Genaissance, the expected growth and development of Genaissance`s business and market opportunities, such as its base services business and its pharmacogenomic product pipeline, the anticipated growth of European operations and the expected release of the FAMILION(TM) Test. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2004, and in other filings we make with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

GENAISSANCE PHARMACEUTICALS, INC.
Statements of Operations
(Unaudited)
(In thousands, except per share data)

Three Months Ended
March 31,
2004 2003
License and service revenue $2,868 $2,139
Laboratory services 860 --

Total revenue 3,728 2,139

Operating Expenses:
Cost of laboratory services 861 --
Research and development 5,012 4,739
General and administrative 2,358 2,059

Total operating expenses 8,231 6,798

Loss from operations (4,503) (4,659)

Other income 75 134
Interest expense (180) (201)

Loss before benefit from income taxes and
equity in loss of affiliate (4,608) (4,726)

Income tax benefit 49 --
Equity in loss of affiliate (150) --

Net loss (4,709) (4,726)

Preferred stock dividends and accretion (110) --
Beneficial conversion feature of warrant (6) --

Net loss attributable to common stockholders $(4,825) $(4,726)

Net loss per common share, basic and diluted $(0.21) $(0.21)

Weighted average shares used in computing
Net loss per common share 23,194 22,865


Balance Sheet Data
(in thousands)
(unaudited)
March 31, Dec. 31,
2004 2003
Cash, cash equivalents
and marketable securities $11,431 $16,804
Working capital 9,544 14,195
Total assets 29,821 35,589
Long term debt 8,613 9,118
Stockholders` equity 3,712 8,397

[ollihat]

Was haltet Ihr von plötzlichem Herztod?
Soll in jüngeren Jahren häufiger vorkommen als man denkt!

GNSC hat den FAMILION Test auf den Markt gebracht, mit dem Herzrhytmusstörungen erkannt werden können, die zum plötzlichen Herztod führen.
Der Test soll besser sein als ein Elektrokardiogramm!

Was haltet Ihr von : Strong Buy?

[Chevalier_deSeingalt]

nice move

[Rente mit 40]

Wieso Stong Buy?? Erstens haben die mir für meine schöne Lark einen Sack voll von diesen Dingern gegeben. Und zweitens! Nur weil die was auf den Markt bringen, heißt das noch lange nicht, dass jemand die Tests auch kauft!!!! Oder?? Erst mal auf Umsatz warten. Wenn der kommt, dann kann man zum Einstieg blasen. Alles andere ist Zocken. Und ob sich das mit den Test auch noch finanziell rechnet ist ja auch eine Frage. Sprich Kosten und Zeitdruck. Ich sehe hier noch nicht die Bäume in den Himmel wachsen.

Ausserdem. Wie groß ist eigentlich der Markt für so ein Zeug ????